WO2022211796A1 - Détection de salmonella à partir d'un échantillon environnemental - Google Patents

Détection de salmonella à partir d'un échantillon environnemental Download PDF

Info

Publication number
WO2022211796A1
WO2022211796A1 PCT/US2021/025053 US2021025053W WO2022211796A1 WO 2022211796 A1 WO2022211796 A1 WO 2022211796A1 US 2021025053 W US2021025053 W US 2021025053W WO 2022211796 A1 WO2022211796 A1 WO 2022211796A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
mixture
seq
sample
sequence
Prior art date
Application number
PCT/US2021/025053
Other languages
English (en)
Other versions
WO2022211796A8 (fr
Inventor
Preetha BISWAS
Robert S. DONOFRIO
Lei Zhang
Lin WALKER
Andrew Michael LASECK
Debra Lynn FOTI
Weisley David COLANGELO
Vimukthi A.A. SENEVIRATHNE
Ariel FOX
Jolien WEYTENS
Original Assignee
Neogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neogen Corporation filed Critical Neogen Corporation
Priority to PCT/US2021/025053 priority Critical patent/WO2022211796A1/fr
Publication of WO2022211796A1 publication Critical patent/WO2022211796A1/fr
Publication of WO2022211796A8 publication Critical patent/WO2022211796A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions

Definitions

  • the present disclosure relates to the detection of Salmonella from an environmental sample.
  • Salmonella Bacterial contamination and infection can pose a serious problem for public health.
  • Salmonella is a harmful pathogen that can be especially problematic in the food industry.
  • compositions, methods, and kits for rapidly detecting Salmonella in samples, such as environmental samples.
  • the provided compositions, methods, and kits enable determining presence or absence of Salmonella in environmental samples without enrichment or prolonged incubation prior to performing the detection assay itself.
  • a benefit of the provided methods is that results can be obtained in a short time (e.g., about 1-2 hours from sample collection), compared to conventional methods that may take 24 hours or more. Due to low sensitivity, conventional methods require enrichment of the sample to increase the concentration of target organisms, or other types of prolonged incubation steps required to increase the concentration of target molecules to detectable levels.
  • the present disclosure provides improvements and benefits compared to such conventional methods.
  • the present disclosure provides a method for determining the presence or absence of target bacteria in a sample, comprising the steps of: (i) providing a sample; (ii) contacting an aliquot of the sample with a lysis mixture under conditions to lyse at least a portion of cells in the aliquot, thereby generating a lysate; (iii) contacting an aliquot of the lysate with a detection mixture, thereby generating an assay mixture; (iv) in the assay mixture, reverse transcribing a target RNA of the target bacteria to form target cDNA and inplifying the target cDNA by heliease-dependent amplification (HD A); and (v) detecting presence or absence of the amplified target cDNA, thereby determining the presence or absence of the target bacteria in the sample.
  • the aliquot of the sample may be a portion of the sample.
  • the aliquot of the lysate may be a portion of the lysate.
  • the method does not include enrichment for cells in the sample. In some embodiments, the method does not include a prolonged incubation period to increase concentration of the target RNA prior to contacting the sample with the lysis mixture,
  • the sample comprises bacteria, that is not the target bacteria, in some embodiments, the sample is an environmental sample. In some embodiments, the sample is collected from an environment comprising a low concentration of the target bacteria cells. In some embodiments, the method is of sufficient sensitivity to detect the presence of the target bacteria from a sample having as little as about 30-60 colony forming units (CPU) of the target bacteria.
  • CPU colony forming units
  • the sample is taken from a surface that is a solid, and the concentration of the target bacteria cells on the surface is a low concentration.
  • the solid surface further comprises microflora that is not the target bacteria.
  • the solid surface comprises from about 10 to about 200 CFU of the target bacteria per 1 square inch of the solid surface;
  • the solid surface comprises from about 10 to about 100 CFU of the target bacteria per 1 square inch of the solid surface; or
  • the solid surface comprises from about 10 to about 50 CFU of the target bacteria per 1 square inch of the solid surface.
  • the target bacteria is of the genus Salmonella and the target RNA comprises a Salmonella RNA sequence.
  • the target RNA comprises a Salmonella RNA sequence of the 23S ribosomal RNA.
  • the method further comprises collecting the sample to be provided i step (i), wherein the sample is collected from an environment that is being tested for bacteria] contamination by the target bacteria.
  • the sample is collected with a pre-moistened swab or sponge.
  • the method further comprises a step of pre-treating an aliquot of the sample to remove nucleic acids not associated with intact cells, thereby generating a pre-treated sample; and the step of contacting the aliquot of the sample with the lysis mixture comprises contacting an aliquot of the pre-treated sample with the lysis mixture under conditions to lyse at least a portion of cells in the aliquot of the pre-treated sample.
  • the aliquot of the pre-treated sample may he a portion of the pre-treated sample, in some embodiments, the step of pre-treating the aliquot of the sample comprises contacting the aliquot of the sample with a pre-treatment mixture under conditions to remove nucleic acids not associated with intact cells in the aliquot of the sample.
  • the pretreatment mixture comprises a nuclease that cleaves nucleic acids and the lysis mixture comprises a component that inactivates the nuclease.
  • the nuclease is micrococcal nuclease, in some embodiments, the pre-treatment mixture further comprises a divalent salt and the component that inactivates the nuclease is a divalent ion chelator.
  • the pre-treatment mixture is lyophilized.
  • the lysis mixture comprises at least one lytic enzyme and at least one protease, in some embodiments, the lysis mixture further comprises Chelex-100.
  • the step of detecting presence or absence of the amplified target cDNA comprises: (i) detecting a level of the amplified target cDNA above a threshold level and thereby determining the presence of the target bacteria in the environmental sample; or (ii) detecting a level of the amplified target cDNA below a threshold level and thereby determining the absence of the target bacteria in the environmental sample.
  • the step of detecting comprises measuring a fluorescent readout indicative of the presence of the amplified target cDNA.
  • the detection mixture comprises at least one probe for detecting the amplified target cDN A.
  • Hie probe may be a fluorescent molecular probe.
  • the probe is a conditional fluorescent hybridization probe that emits fluorescence when hybridized to a nucleic acid molecule comprising the nucleic acid sequence of: (i) CAC GTA GOT GAA GIG ATT TAG TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6; or (ii) CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7.
  • the probe comprises the nucleic acid sequence of: CCA TGA GTA AAT rCAC TTC ACC TAC GTG (SEQ ID NO: 5), or a sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • the detection mixture further comprises RNase H2.
  • the detection mixture further comprises a helicase, an energy ' source for the heliease, a DNA polymerase, a reverse transcriptase, and dNTPs.
  • the detection mixture further comprises a single-stranded binding protein.
  • the detection mixture further comprises a control RNA and a control probe that is able to detect amplification products of the control RNA.
  • the detection mixture further comprises a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of the target RNA and a second primer having hybridization specificity for a smgie-stranded nucleic acid region comprising a nucleic acid sequence complementary' to the target RNA sequence.
  • the first primer may comprise the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3 and the second primer may comprise the nucleic acid sequence of 5’ GAG AAG GCA CGC TGA CAC 3’ (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the detection mixture further comprises (i) an enzyme that binds uracil in a DNA strand and converts it into an apurinic site; (ii) an enzy me that cleaves DN A at apurinic sites; and (hi) a specialized dNTP that is recognized by the enzyme of (i).
  • the enzyme that binds uracil in a DNA strand and converts it into an apurinic site is a uracil DNA giycosylase
  • the enzyme that cleaves DNA at apunnic sites is Endonuclease VIII and the specialized dNTP that is recognized by the enzyme of (i) is dUTP.
  • At least one of the lysis mixture and the detection mixture is lyophilized
  • the time from providing the environmental sample to detecting at least some of the amplified target cDNA is 2 hours or less. In some embodiments, the provided environmental sample has been stored at 4°C for up to 24 hours.
  • the present disclosure provides a kit comprising a first mixture and a second mixture, wherein the first mixture comprises micrococcal nuclease and a divalent salt and the second mixture comprises a divalent ion chelator, at least one lytic enzyme and at least one protease.
  • the divalent salt is calcium chloride (CaCb) and the divalent ion chelator is EGTA.
  • the at least one lytic enzyme comprises lyosozyrne and mutanolysin and the at least one protease is proteinase K.
  • the kit further comprises a third mixture, said third mixture comprising a chelating resin.
  • the chelating resin may be Chelex-100.
  • the kit further comprises a fourth mixture, said fourth mixture comprising a lie!icase, an energy' source for the helicase, a DNA polymerase, a reverse transcriptase, and dNTPs.
  • the fourth mixture further comprises a single-stranded binding protein.
  • the fourth mixture further comprises (i) an enzyme that binds uracil in a DNA strand and converts it into an apurinic site; (ii) an enzyme that cleaves DNA at apunnic sites; and (iii) a specialized dNTP that is recognized by the enzyme of (i).
  • the fourth mixture further comprises a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of the Salmonella 23 S ribosomal RNA and a second primer having hybridization specificity' for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the nucleic acid sequence of the Salmonella 23S ribosomal RNA.
  • the first primer may comprise the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3) or a sequence with at least 90% sequence identity' to SEQ ID NO: 3 and the second primer may comprise the nucleic acid sequence of 5 ' GAG AAG GCA CGC TGA CAC 3' (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the fourth mixture further comprises at least one probe.
  • one of the at least one probe is a conditional fluorescent hybridization probe that emits fluorescence when hybridized to a nucleic acid molecule comprising the nucleic acid sequence of: (i) CAC GTA GGT GAA GTG ATT TAC TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6; or (ii) CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7.
  • one of the at least one probe comprises the nucleic acid sequence of: CCA TGA GTA AAT rCAC TTC ACC TAC GTG (SEQ ID NO: 5), or a sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • the first, second, third and/or fourth mixture is lyophiiized.
  • the first mixture is lyophiiized and upon resuspension of the first mixture, the concentration of micrococcal nuclease ranges from 0.1-0.3 Units/pL and the concentration of the divalent salt ranges from 2-6 mM.
  • the second mixture is lyophiiized and upon resuspension of the second mixture, the concentration of the divalent ion chelator ranges from 2-5 mM.
  • the kit is for use in a method of determining the presence or absence of target bacteria in an environmental sample.
  • the present disclosure provides a kit comprising a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of Salmonella 23S ribosomal RNA and a second primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the nucleic acid sequence of the Salmonella 23S ribosomal RNA.
  • the first primer comprises the nucleic acid sequence of 5 ’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3 and the second primer comprises the nucleic acid sequence of 5" GAG AAG GCA CGC TGA CAC 3’ (SEQ IB NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the kit further comprises at least one probe for detecting a nucleic acid molecule comprising the nucleic acid sequence of: CAC GTA GGT GAA GTG ATT TAC TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6.
  • the kit further comprises at least one probe for detecting a nucleic acid molecule comprising the nucleic acid sequence of: CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7.
  • the kit further comprises at least one probe that comprises the nucleic acid sequence of: CCA TGA GTA AAT rC AC TTC ACC TAC GTG (SEQ ID NO: 5), or a sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • the first primer, the second primer and the probe are lyophihzed.
  • the present disclosure provides a primer comprising or consisting of the nucleic acid sequence of GAG AAG GCA CGC TGA CAC (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the present disclosure provides a primer comprising or consisting of the nucleic acid sequence of CTG ACT TCA GCT CCG TGA GTA AAT (SEQ ID NO: 3) or a sequence with at least 90%) sequence identity to SEQ ID NO: 3.
  • the present disclosure provides a composition comprising at least one of: (i) a primer comprising or consisting of the nucleic acid sequence of GAG AAG GCA CGC TGA CAC (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2; and (ii) a primer comprising or consisting of the nucleic acid sequence of CTG ACT TCA GCT CCG TGA GTA AAT (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3.
  • the present disclosure provides a lyophitized composition comprising micrococcal nuclease and calcium chloride (CaCh), wherein, upon resuspension of the lyophihzed composition, the concentration of micrococcal nuclease ranges from 0.1- 0.3 Umts/ ⁇ L and the concentration of CaCh ranges from 2-6 mM. In some embodiments, upon resuspension of the lyophihzed composition, the concentration of micrococcal nuclease is 0.22 ujnits ⁇ LE an the concentration of CaCb is 4.1 mM.
  • CaCh calcium chloride
  • the present disclosure provides a iyophiiized composition
  • a iyophiiized composition comprising (i) at least one of iyosozyme and mutanolysin; (li) at least one of proteinase K and achromopeptidase; and (iii) EGTA, wherein, upon resuspension of the Iyophiiized composition, the concentration of lysozyme ranges from 0-1 mg/mL, the concentration of mutanolysin ranges from 0-30 Umts/mL, the concentration of proteinase K ranges from 0-1 mg/mL, the concentration of achromopeptidase ranges from 0-150 Units/mL, and the concentration of EGTA ranges from 2-5 niM.
  • the concentration of lysozyme is 0.8 mg/mL
  • the concentration of mutanolysin is 20 Units/mL
  • the concentration of proteinase K is 0.8 mg/mL
  • the concentration of achromopeptidase is 85.6 Units/mL
  • the concentration of EGTA is 2.6 mM.
  • FIG. 1 shows an illustrative sequence of steps for a Salmonella detection method of the present disclosure.
  • the method comprises pre-treatment, lysis and a Salmonella detection assay. Details of each of these steps is further described elsewhere by the present disclosure, in some cases, as separate methods of pre-treatment, lysis and nucleic acid amplification and detection, respectively, which can be combined in the sequence shown.
  • the illustrative method comprises pre-treating an aliquot of a sample (e.g., a provided environmental sample) to remove nucleic acids not associated with intact cells, thereby generating a pre-treated sample; contacting an aliquot of the pre-treated sample with a lysis mixture comprising lytic enzymes under conditions to lyse at least a portion of cells in the aliquot of the pre-treated sample, thereby generating a lysate; contacting an aliquot of the lysate with a detection mixture comprising components for amplification and detection of Salmonella target nucleic acids; and performing the Salmonella detection assay.
  • a sample e.g., a provided environmental sample
  • FIG. 2A-FIG. 2G are graphs showing the detection of Salmonella enterica subspecies and serovars with primers and probe designed for amplification and detection of Salmonella nucleic acids.
  • FIG. 3A-FIG. 3B are graphs showing amplification and detection results of exclusive bacterial strains with primers and probe designed for amplification and detection of Salmonella nucleic acids.
  • FIG. 4 is a graph showing amplification signals observed for S. Typhimurium.
  • FIG. 5 is a graph showing amplification signals observed for no template control (NTC) samples that did not have Salmonella cells present.
  • kits and/or reagents are generally carried out in accordance with manufacturer's guidance and/or protocols and/or parameters unless otherwise noted.
  • the words “preferred” and “preferably” refer to embodiments of the disclosure that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the invention. [0039] About: The word “about” is understood to modify numbers recited in the specification and claims whether or not explicitly stated. The term “about” is intended to take into account standard measurement errors and encompass rounding off.
  • Aliquot as used with reference to an aliquot of a sample or lysate means a portion or all of the stated sample or lysate that is used for further processing, such as downstream steps in a method.
  • control RNA refers to an RNA molecule added to a detection mixture or an assay mixture for purposes of serving as a positive internal control for amplification and/or detection by methods described herein.
  • a control RNA can be detected with a control probe.
  • a “control probe” is a probe that is designed to detect amplification products of the control RNA.
  • Downstream methods refers to one or more additional methods (e.g., one or more additional steps) or assays (e.g., a detection assay) that are carried out.
  • the one or more additional methods or assays may be carried out after the stated procedure is initiated, or after the stated procedure has been performed.
  • a method that is downstream to cell lysis may be carried out after lysis begins, and/or after a lysis step generates a lysate.
  • a downstream method or downstream assay does not necessarily follow directly after the stated procedure. For example, additional intervening steps may be included between the stated procedure and the downstream method or assay.
  • Enrichment refers to expansion of target cells (e.g., target bacteria cells). Enrichment may comprise exposing a sample comprising target bacteria cells to cell growth conditions that promote increasing the number of the target bacteria cells.
  • An enrichment broth may comprise both beneficial compounds for the growth of the target microbe (e.g., target bacteria), as well as inhibitory compounds for other microbes that are detrimental to the growth of the target microbe or to downstream assay steps.
  • Continuing enrichment of the target microbe on different selective media is a known method of assaying for the presence of the target microbe.
  • Methods known in the art for example for food samples or food production environments or pharmaceutical environments, can be found in the USDA Microbiology Laboratory Guidebook (USDA-MLG), or the U.S. Food and Drug Administration (FDA) Bacteriological Analytical Manual (FDA-BAM).
  • Environmental sample refers to a sample collected from the environment.
  • an environmental sample is collected from the environment in a room or a building where foods and/or beverages are produced and/or processed, such as that of a manufacturing plant or a commercial kitchen.
  • environmental samples may be collected from food/beverage production, processing and/or service sites.
  • Environmental samples may be collected from both food contact surfaces (e.g., sheers, mixers, utensils or conveyors) and non-food contact surfaces (e.g., floors, drains, carts or equipment housing).
  • Environmental surfaces may be composed of a variety of materials or combinations of materials, such as stainless steel, plastic, ceramic tile, sealed concrete, or rubber.
  • environmental samples may be collected from industrial food equipment surfaces. Additional examples of environmental samples are provided below.
  • Helicase refers herein to an enzyme capable of unwinding a double-stranded nucleic acid enzymatically.
  • helicases are enzymes that are found in all organisms and in all processes that involve nucleic acids such as replication, recombination, repair, transcription, translation and RNA splicing.
  • Helicases use the energy of nucleoside triphosphate (for example ATP) hydrolysis to break the hydrogen bonds that hold the strands together in duplex DNA and RNA.
  • a helicase may translocate along DNA or RNA in a 5' to 3' direction or in the opposite 3’ to 5' direction.
  • Helicases can be found in prokaryotes, viruses, archaea, and eukaryotes or recombinant forms of naturally occurring enzymes as well as analogues or derivatives having the specified activity.
  • Naturally occurring DNA helicases described by Komberg and Baker in chapter 11 of their book, DNA Replication, W.H. Freeman and Company (2 nd ed. (1992)), include E. coli helicase I, II, III, & IV, Rep, DnaB, PriA, PcrA, T4 Gp41 helicase, T4 Dda helicase, T7 Gp4 helicases, SV40 Large T antigen, yeast RAD.
  • Additional helicases include RecQ helicase (Harmon and Kowalczykowski, J. Biol. Chem. 276:232-243 (2001)), thermostable UvrD helicases from T. tengcongensis and T. thermophilus (Collins and McCarthy, Extremophiles. 7:35-41. (2003)), thermostable DnaB helicase from T. aquaticus (Kaplan and Steitz, J. Biol. Chem. 274:6889-6897 (1999)), and MCM helicase from archaeal and eukaryotic organisms (Grainge et ak, Nucleic Acids Res. 31:4888-4898 (2003)).
  • Helicase-dependent amplification refers to an in vitro method for amplifying nucleic acids by using a helicase for unwinding a double-stranded nucleic acid to generate templates for primer hybridization and subsequent primer-extension. This process utilizes two oligonucleotide primers, each hybridizing to the 3'-end of either the sense strand containing the target sequence or the anti- sense strand containing the reverse complementary target sequence.
  • the HDA reaction is a general method for helicase-dependent nucleic acid amplification.
  • Hybridization refers to binding of a single-stranded nucleic acid to a complementary single-stranded nucleic acid, preferably under conditions in which binding occurs only specifically to a nucleic acid region having a complementary sequence and not to other regions. In some embodiments, hybridization occurs between an oligonucleotide and a complementary region of a single-stranded nucleic acid. The specificity of hybridization may be influenced by the length of the oligonucleotide, the temperature in which the hybridization reaction is performed, the ionic strength, and the pH.
  • hybridization occurs between a primer and a complementary single-stranded region on a target nucleic acid to facilitate polymerase-dependent replication of the target nucleic acid and/or reverse-transcriptase-dependent synthesis of cDNA from a target nucleic acid serving as an RNA template.
  • hybridization occurs between a probe and a nucleic acid of interest.
  • hybridization refers to binding of an oligonucleotide primer to a region of the single-stranded nucleic acid template under conditions in which the primer binds only specifically to its complementary sequence on one of the template strands, not other regions in the template.
  • hybridization occurs between two single-stranded nucleic acids that are at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary.
  • Hybridization specificity refers to the ability of a molecule comprising or consisting of a single-stranded polynucleotide, or a portion of said molecule, to anneal to a complementary region of a polynucleotide.
  • the degree of hybridization may vary depending on conditions (such as temperature, pH, buffers, etc.) and depending on level of complementarity.
  • a molecule or portion thereof may have hybridization specificity for a region of a polynucleotide that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the stated molecule or portion thereof.
  • Identity refers to a relationship between two or more sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between sequences, as determined by the number of matches between strings of two or more residues (amino acid or nucleic acid). Identity measures the percent of identical matches between two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., “algorithms”). Identity of related sequences can be readily calculated by known methods. Percent identity may be determined, for example, by comparing sequence information using sequence alignment programs known to those skilled in the art.
  • Incubation refers to the process of exposing something (e.g., a sample) to a set of conditions (e.g, temperature, specific reagents, etc.) for a period of time.
  • a “prolonged incubation” refers to incubation for a period of time that is longer than at least one hour or at least two hours.
  • Isothermal The term “isothermal” used in the context of helicase-dependent amplification refers to nucleic acid amplification that occurs at a constant temperature.
  • Lysis refers to breaking open cells (e.g., bacterial cells) to release its contents (e.g., nucleic acids). Lysis may be achieved by contacting a sample comprising cells with a lysis buffer comprising lytic components. Examples of lytic components may be, but are not limited to, detergents, enzymes or denaturing salts. A fluid comprising the contents of lysed cells is referred to as a “lysate.”
  • Lytic enzyme refers to any enzyme that promotes lysis of a cell.
  • the cell is a bacterial cell.
  • lytic enzymes promote lysis of a bacterial cell by hydrolyzing the bacterial cell wall.
  • Non-limiting examples of lytic enzymes are lysozyme and mutanolyisn.
  • Melting The terms “melting”, “unwinding” or “denaturing” refer to separating all or part of two complementary strands of a nucleic acid duplex.
  • Nucleic acid The terms “nucleic acid molecule,” “nucleic acid,”
  • oligonucleotide and “polynucleotide” may be used interchangeably, and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and/or non-natural nucleotides.
  • Illustrative nucleic acids or polynucleotides include, but are not limited to, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs) or hybrids thereof.
  • Nucleic acid sequence refers to the linear sequence of nucleotides of the nucleic acid molecule or polynucleotide.
  • the nucleic acid may be a short molecule (approximately 13-25 nucleotides long and/or less than 200 nucleotide residues) and may then be termed an “oligonucleotide.”
  • the term nucleic acid molecule, and in particular DNA or RNA molecule refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules, plasmids, supercoiled DNA and chromosomes.
  • DNA includes, but is not limited to, cDNA, genomic DNA, plasmid DNA, synthetic DNA, and semi-synthetic DNA.
  • Those molecules which are double stranded nucleic acid molecules may be nicked or intact.
  • the double stranded or single-stranded nucleic acid molecules may be linear or circular.
  • the duplexes may be blunt ended or have single-stranded tails.
  • duplex refers to a nucleic acid molecule that is double-stranded in whole or part.
  • the single-stranded molecules may have secondary structure in the form of hairpins or loops and stems.
  • Nucleic acids may be isolated, cloned or synthesized in vitro by means of chemical synthesis. Any of the above described nucleic acids may be subject to modification where individual nucleotides within the nucleic acid are chemically altered (for example, by methylation). Modifications may arise naturally or by in vitro synthesis.
  • Presence or absence when used in reference to detecting presence or absence of amplified nucleic acid or determining presence or absence of a target bacteria, refers to the state of having or not having the stated composition (e.g., amplified nucleic acid or target bacteria).
  • the presence and absence assay signal rely on the limit of detection of the assay.
  • absence does not necessarily mean absolute absence; instead, a composition may be determined as absent if there is a low level, such as below a negative control threshold, that is detected or if the concentration of the composition in a test sample is close to the limit of detection or much lower than the limit of detection of the assay.
  • Presence may be determined by a specific cut-off, below which the composition is not considered to be present. For samples with concentrations close to the limit of detection, multiple replicates may be necessary to detect presence.
  • Primer refers to a single-stranded nucleic acid capable of binding to a single-stranded region on a target nucleic acid to facilitate polymerase-dependent replication of the target nucleic acid and/or reverse-transcriptase- dependent synthesis of cDNA from a target nucleic acid serving as an RNA template.
  • a primer is capable of binding to a region on an RNA molecule.
  • a primer is capable of binding to a single-stranded region on a DNA or cDNA molecule.
  • a primer is capable of binding to both a single-stranded region on an RNA molecule and a single-stranded region on a DNA or cDNA molecule.
  • the term “primer pair” refers to a set of two primers, one serving as the forward primer and the other as the reverse primer, each binding to one of the two ends of a single-stranded region on a target nucleic acid.
  • a primer of the present disclosure generally has less than 50 residues.
  • a primer of the present disclosure is in a size range having a lower limit of about 5 to about 15 residues and an upper limit of about 25 to about 35 residues.
  • a primer of the present disclosure may comprise 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 residues.
  • Probe refers to a labeled molecule or portion thereof that is designed to detect a nucleic acid of interest.
  • the term “probe” is interchangeable with the term “molecular probe.”
  • detect is interchangeable with the term “recognize” and refers to the ability of the probe to identify the nucleic acid of interest.
  • a probe is a single- stranded nucleic acid comprising one or more complementary sequences to the nucleic acid of interest. When the probe is placed in contact with a sample under conditions that allow the probe to hybridize with the nucleic acid of interest, the nucleic acid of interest is detected.
  • the label of the probe can be a tag, such as a radioactive or chemical tag, that allows hybridization of the probe to the nucleic acid of interest to be visualized.
  • the probe is a fluorescent molecular probe (also referred to herein as a “fluorescent probe”), which is a probe that emits fluorescence.
  • a fluorescent molecular probe is a conditional fluorescent hybridization probe.
  • the probe is a conditional fluorescent hybridization probe that emits fluorescence when hybridized to the nucleic acid of interest.
  • the nucleic acid of interest is an amplicon produced by heli case-dependent amplification (HDA) according to methods of the present disclosure.
  • HDA heli case-dependent amplification
  • Salmonella refers to all species of the gram-negative rod-shaped bacteria in the genus of Salmonella, including S. bongori, S. enterica, S. enterica subsp. arizonae, S. enterica subsp. diarizonae, S. enterica subsp. enterica, S. enterica subsp. houtenae, S. enterica subsp. indica, and S. enterica subsp. salamae. “ Salmonella ” also refers to all serotypes, including, for example, S. Typhimurium, S. Blockley, and S. Reading.
  • Sensitivity when used in reference to a detection method or assay is the proportion of actual positive samples that are correctly identified as positive by the method or assay.
  • Actual positive samples are generally defined by using a validated assay used to detect the presence of a target microbe (e.g., target bacteria).
  • the actual positives are defined by a method comprising culturing a sample to determine whether target microbes are present.
  • one or more positive control samples are used as actual positive samples.
  • one or more positive control samples are used alongside test samples that may or may not be actual positive samples.
  • a method is described as having “sufficient sensitivity,” which refers to the ability of the method to correctly identify as positive an actual positive sample.
  • a method may have sufficient sensitivity under certain conditions.
  • Specificity when used in reference to a detection method or assay is the proportion of actual negative samples that are correctly identified as negative by the method or assay.
  • Actual negative samples are generally defined by using a validated assay used to detect the presence of a target microbe (e.g., target bacteria).
  • the actual negatives are defined by a method comprising culturing a sample to determine whether target microbes are present.
  • one or more negative control samples are used as actual negative samples.
  • one or more negative control samples are used alongside test samples that may or may not be actual negative samples.
  • a negative control sample comprises a bacterium that is not the target bacterium.
  • Target bacteria refers to one or more species of bacteria that are targeted for detection and/or quantification in a sample, such as an environmental sample.
  • the target bacteria are any bacteria of the genus Salmonella.
  • Target nucleic acid refers to a nucleic acid molecule, or portion thereof, that is present in target bacteria.
  • the target nucleic acid is detected using nucleic acid detection methods. Methods for detecting a target nucleic acid may be used for purposes of determining the presence or absence of the target bacteria in a sample.
  • a target nucleic acid is detected using the compositions and methods provided by the present disclosure.
  • a target nucleic acid is detected using methods comprising helicase- dependent amplification (HD A). In such cases, the target nucleic acid is amplified according to HDA methods and is referred to as an HDA target nucleic acid.
  • HD A helicase- dependent amplification
  • the term “HDA target nucleic acid” refers to a whole or part of nucleic acid to be selectively amplified and which is defined by 3’ and 5’ boundaries.
  • the HDA target nucleic acid may also be referred to as a fragment or sequence that is intended to be amplified.
  • the size of the HDA target nucleic acid to be amplified may be, for example, in the range of about 50 base pairs (bp) to about 5000 bp. In preferred embodiments, the size of the HDA target nucleic acid to be amplified is 50-150 bp.
  • the HDA target nucleic acid may be contained within a longer double-stranded or single-stranded nucleic acid.
  • the HDA target nucleic acid may be an entire double-stranded or single-stranded nucleic acid. If the initial nucleic acid provided for an HDA method is RNA, the RNA (or a region of the RNA) is reverse transcribed into a cDNA molecule and the cDNA is amplified by a DNA polymerase.
  • the HDA target nucleic acid is considered to be the initial RNA because the RNA is present in target bacteria and the reverse-transcribed copy of the RNA (i.e., the cDNA) is what is being amplified by HDA.
  • Salmonella is a genus of gram-negative bacteria comprising two recognized species, Salmonella enterica (S. enter ica) and Salmonella bongori ( S . bongori).
  • S. ent erica is divided into six subspecies: S. enterica subsp. arizonae, S. enterica subsp. diarizonae, S. enterica subsp. enterica, S. enterica subsp. houtenae, S. enterica subsp. indica, and S. enterica subsp. salamae.
  • Salmonella spp. is sometimes used in the art in place of the phrase “ Salmonella species,” and may refer to all species and subspecies of Salmonella or to specific species or subspecies, depending on the context.
  • S. enterica has over 2500 known serovars (also referred to as “serogroups” or “serotypes”). Serovars are classified based on antigens presented by these organisms. Antibodies for particular antigens can be used to serotype bacteria.
  • Salmonella species can cause illness.
  • Two main groups of Salmonella serotypes known to cause illness are the typhoidal serotypes and nontypohoidal serotypes. Both typhoidal and nontyphoidal infection can cause salmonellosis, a symptomatic infection with common symptoms including diarrhea, fever, abdominal cramps, and vomiting. In some cases, Salmonella infection can be fatal.
  • Nontyphoidal serotypes can be transferred from animal -to-human and from human-to-human. Infection can occur when a person ingests foods that contain these bacteria. Nontyphoidal serotypes can cause bloodstream infections with varied symptoms including fever, hepatosplenomegaly, and respiratory symptoms. Nontyphoidal serotypes include Salmonella enterica serotype Typhimurium, Salmonella enterica serotype Enteritidis, and Salmonella enterica serotype Blockley. Typhoidal Salmonella serotypes can be transferred from human-to-human. Typhoidal serotypes can cause food-borne infection, typhoid fever and paratyphoid fever. Typhoidal serotypes include Salmonella enterica serotype Typhi and Salmonella enterica serotype Paratyphi A.
  • Salmonella infections are caused by food or water contaminated with the bacteria. Contamination can occur when food or water comes in contact with feces of infected people or animals.
  • a variety of foods can be the source of Salmonella infection. Examples of foods that have the potential to be contaminated with Salmonella include sprouts and other vegetables, eggs, chicken, pork, fruits, and processed foods.
  • Recently (between 2017-2019) human outbreaks of Salmonella enterica serotype Reading in the U.S. and Canada have been linked to the consumption of raw turkey products. Groups that are most susceptible to infection include children, pregnant women, elderly people, and those with weakened immune systems.
  • the present disclosure provides methods for rapid detection of Salmonella from environmental samples via detection of Salmonella target nucleic acids.
  • the methods comprise the steps of providing an environmental sample to be tested; contacting an aliquot of the environmental sample with a lysis mixture under conditions to lyse at least a portion of cells in the aliquot, thereby generating a lysate; contacting an aliquot of the lysate with a detection mixture, thereby generating an assay mixture; in the assay mixture, reverse transcribing target RNA to form target cDNA and amplifying the target cDNA by helicase-dependent amplification (HD A); and detecting presence or absence of the amplified target cDNA, to thereby determine the presence or absence of Salmonella in the environmental sample.
  • the provided methods further comprise a step of pre-treating the aliquot of the environmental sample to remove nucleic acids not associated with intact cells prior to contacting the aliquot with the lysis mixture.
  • a sample is provided for purposes of testing for the presence or absence of target bacteria in the sample.
  • the sample can be any sample that may comprise target bacteria.
  • the provided sample is suspected of being contaminated with bacteria, for example, the target bacteria.
  • providing a sample to be tested comprises providing a sample to confirm absence of bacterial contamination, for example, absence of the target bacteria.
  • the target bacteria are of the genus Salmonella.
  • the presence or absence of target bacteria can be analyzed in a test environmental sample that is derived from food processing and/or beverage processing environmental sources.
  • food processing and/or beverage processing environmental sources include food-handling surface samples (e.g., conveyor belts, blades, cutting surfaces, mixing equipment surfaces, filters, storage containers), room samples (e.g., walls, floors, drains, ventilation equipment), and cleaning equipment (e.g., hoses, cleaning tools).
  • the sample is an environmental sample.
  • an environmental sample is collected from the environment in a room or a building where foods and/or beverages are produced and/or processed.
  • environmental samples may be collected from food/beverage production, processing or service sites.
  • the environmental sample is from an environment comprising a low concentration of target bacteria cells (e.g., Salmonella cells).
  • a “low concentration” of target bacteria cells refers to a concentration that is difficult to detect without amplifying the amount of an indicator associated with the target bacteria (such as by amplifying the amount of cells or the amount of target bacterial nucleic acids).
  • the environmental sample is from an environment that can be tested for bacterial contamination of the target bacteria.
  • the environment is a surface that is a solid comprising a low concentration of target bacteria cells.
  • a low concentration of target bacteria is at most 200 colony forming units (CFU) per 1 square inch of a solid surface.
  • a low concentration of target bacteria is at most 100 CFU per 1 square inch of a solid surface.
  • a low concentration of target bacteria is at most 50 CFU per 1 square inch of a solid surface. In some embodiments, a low concentration of target bacteria is at most 5 CFU per 1 square inch of a solid surface. In some embodiments, a low concentration of target bacteria is at most 200 CFU per 1 milliliter of a collected sample. In some embodiments, a low concentration of target bacteria is at most 100 CFU per 1 milliliter of a collected sample. In some embodiments, a low concentration of target bacteria is at most 50 CFU per 1 milliliter of a collected sample. In some embodiments, a low concentration of target bacteria is at most 5 CFU per 1 milliliter of a collected sample.
  • the solid surface comprises from about 10 to about 200 colony forming units (CFU) of target bacteria per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 10 to about 100 CFU of target bacteria per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 10 to about 50 CFU of target bacteria per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 5 to about 200 colony forming units (CFU) of target bacteria per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 5 to about 100 CFU of target bacteria per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 5 to about 50 CFU of target bacteria per 1 square inch of the solid surface. In some embodiments, the target bacteria are of the genus Salmonella.
  • samples such as environmental samples
  • a collection device collects an environmental sample from a surface.
  • the collection device is a swab.
  • the swab may be made from various materials, such as, but not limited to, cotton, polyester or polyurethane.
  • the swab is pre-moistened, such as in solution.
  • the swab may be pre moistened in buffer or broth.
  • the swab is pre-moistened in neutralizing buffer, buffered peptone water, or culture medium.
  • the volume of the pre-moistening liquid on the swab is about 1-10 mL.
  • the collection device is a sponge.
  • the sponge may be made from various materials, such as, but not limited to, polyurethane.
  • a sponge advantageously samples a larger surface area than other sampling devices.
  • the sponge is pre-moistened.
  • the sponge may be pre-moistened in buffer or broth.
  • the sponge is pre-moistened in neutralizing buffer, buffered peptone water, or culture medium.
  • the volume of the pre-moistening liquid on the sponge is about 10-25 mL.
  • a sample collection device e.g., a swab, a sponge
  • sample material may be eluted (e.g., rinsed, scraped, expressed) from a sample collection device before using the sample material in a method of the disclosure.
  • liquid or solid samples may be diluted in a liquid (e.g., water, buffer, broth).
  • collecting an environmental sample comprises swabbing with the collection device (e.g., swab or sponge) an area of a solid surface.
  • the area is about a lxl inch area, a 4x4 inch area or a 12x12 inch area.
  • swabbing comprises swabbing in multiple directions.
  • the surface is a flat surface.
  • the environmental sample collected comprises from about 5 to about 200 CFU of target bacteria (e.g., Salmonella).
  • the environmental sample collected comprises from about 5 to about 100 CFU of target bacteria (e.g., Salmonella).
  • the environmental sample collected comprises from about 5 to about 50 CFU of target bacteria (e.g., Salmonella).
  • the environmental sample collected comprises from about 10 to about 200 CFU of target bacteria (e.g., Salmonella).
  • Methods and kits of the present invention may include a collection device.
  • compositions and methods for detection of target nucleic acids found in target bacteria cells are Salmonella.
  • a target nucleic acid may be any type of nucleic acid molecule, such as ribonucleic acid (RNA) or deoxyribonucleic acid (DNA).
  • RNA ribonucleic acid
  • DNA deoxyribonucleic acid
  • the target nucleic acid is an RNA, and is also referred to herein as a “target RNA.”
  • a target nucleic acid is abundant in target bacteria, thereby lowering the limit of detection of assays such as those disclosed herein.
  • a target nucleic acid is present at any or all stages of growth for the target bacteria.
  • the target nucleic acid is present in stationary phase and log phase growth.
  • the target bacteria are of the genus Salmonella.
  • a target nucleic acid is present at all stages of growth for Salmonella.
  • a target nucleic acid of the present disclosure comprises a nucleic acid sequence from bacterial 23 S ribosomal RNA (rRNA).
  • the 23 S rRNA is a component of the large subunit of the bacterial ribosome.
  • a target nucleic acid comprises a sequence from Salmonella 23S rRNA.
  • the 23S rRNA is an RNA molecule present in Salmonella at a high copy number.
  • the 23 S rRNA is a highly folded RNA molecule, making some regions inaccessible if they are buried within the folds. Inaccessibility of the target nucleic acid can compromise detection. A target nucleic acid that is inaccessible to detection agents (such as enzymes and primers) may not be easily detected. In some embodiments, the target nucleic acid of the present disclosure, or a region thereof, is accessible to detection methods, such as those disclosed herein.
  • a target nucleic acid of the present disclosure demonstrates specificity for the target bacteria, for example, Salmonella.
  • the target nucleic acid is a region in the 23 S rRNA that is specific to Salmonella enterica serovars and is not present in the closely related Escherichia coli.
  • the target RNA comprises the nucleic acid sequence (read in the 5’ to 3’ direction) of GAG AAG GCA CGC UGA CAC GUA GGU GAA GUG AUU UAC UCA CGG AGC UGA AGU CAG (SEQ ID NO: 1).
  • the target RNA comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1.
  • target nucleic acids provided by the present disclosure is specificity for the bacteria of interest (e.g., Salmonella ), as demonstrated by examples provided herein. Additionally, the present disclosure demonstrates that these target nucleic acids are accessible for detection, for example, by using compositions and methods provided herein.
  • bacteria of interest e.g., Salmonella
  • present disclosure demonstrates that these target nucleic acids are accessible for detection, for example, by using compositions and methods provided herein.
  • Forward and reverse primers as well as probes for the target nucleic acid of the present disclosure can be designed according to known molecular biology techniques.
  • primers according to the present disclosure can be used to reverse transcribe a target RNA to form a corresponding target cDNA.
  • a “corresponding target cDNA” or simply “target cDNA” is a cDNA that is generated by reverse transcribing a target RNA.
  • primers can be used to amplify a target cDNA.
  • a single pair of one forward primer and one reverse primer can be used to reverse transcribe a target RNA to form a corresponding target cDNA and to amplify the target cDNA.
  • Salmonella detection may include use of a first primer comprising the nucleic acid sequence of 5’ GAG AAG GCA CGC TGA CAC 3’(SEQ ID NO: 2) and a second primer comprising the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3).
  • a primer comprising or consisting of the nucleic acid sequence of GAG AAG GCA CGC TGA CAC (SEQ ID NO: 2) or a sequence with at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2. Also provided herein is a primer comprising or consisting of the nucleic acid sequence of CTG ACT TCA GCT CCG TGA GTA AAT (SEQ ID NO: 3) or a sequence with at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3. Also provided are compositions and kits comprising one or more of any of these primers.
  • False positives from lysed cells in the environment has been a problem with previous environmental sampling procedures. For example, methods that rely on detection of target nucleic acids may inadvertently detect nucleic acids from lysed cells existing in the environment. Nucleic acids from lysed cells are also referred to by the present disclosure as “free nucleic acids,” because they have been released from ruptured cells in the environment, such as dead, dying, lysed, or lysing cells in the environment.
  • the present disclosure provides compositions and methods for removing nucleic acids from lysed cells prior to downstream methods, including downstream methods of detecting target nucleic acids from intact cells in an environmental sample.
  • the present disclosure further provides compositions and methods to easily and effectively deactivate reactions that remove nucleic acids from lysed cells so as not to remove nucleic acids from intact, living cells.
  • the provided methods to remove nucleic acids from lysed cells are referred to herein as “pre-treatment.”
  • Pre-treatment comprises use of one or more enzymes that cleave nucleic acids.
  • pre-treatment cleaves DNA and RNA, as well as other single-stranded and double- stranded nucleic acids.
  • the one or more enzymes for pre-treatment may comprise an RNase, a DNase, and/or an enzyme that functions both as an RNase and a DNase.
  • an enzyme for pre-treatment is micrococcal nuclease from Staphylococcus aureus.
  • Methods of the present disclosure also comprise a mechanism to inactivate the one or more enzymes so that nucleic acids from living cells are essentially not cleaved by the enzyme.
  • the phrase “essentially not cleaved” means that the nucleic acids from living cells are not cleaved or only minimally cleaved.
  • the present disclosure provides for a sample pre-treatment to remove nucleic acids from lysed cells prior to lysing intact bacterial cells collected in a sample and other downstream methods.
  • pre-treatment involves a reaction that is active prior to the cell lysis method step of the present disclosure, but inactivated before lysis occurs.
  • the pre-treatment is applied prior to cell lysis and helicase-dependent amplification (HD A) methods.
  • compositions and methods of the present disclosure incorporate a pre-treatment for removing nucleic acids from samples that are not associated with intact Salmonella cells.
  • Pre-treatment according to the present disclosure comprises use of a pre-treatment mixture comprising pre-treatment components.
  • the set of pre treatment components comprises an enzyme that cleaves nucleic acids and a divalent salt required for the enzyme’s activity.
  • the mechanism or component to inactivate the enzyme functions by making the divalent salt inaccessible to the enzyme.
  • a divalent ion chelator may be used to inactivate pre-treatment enzyme activity.
  • divalent ion chelators include the following: ethylenediaminetetraacetic acid (EDTA); BAPTA (l,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) and its derivatives (e.g., BAPTA-AM); EGTA derivatives (e.g., EGTA-AM); citric acid; FURA 2 and its derivatives; RHOD 2 and its derivatives; and FLUO 3 and its derivatives.
  • EDTA ethylenediaminetetraacetic acid
  • BAPTA l,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
  • EGTA derivatives e.g., EGTA-AM
  • citric acid FURA 2 and its derivatives
  • RHOD 2 and its derivatives and FLUO 3 and its derivatives.
  • micrococcal nuclease An example of an enzyme that may be used as a component of pre-treatment is micrococcal nuclease.
  • An example of a divalent salt required for the enzyme’s activity is calcium chloride (CaCh).
  • An example of a mechanism to inactive micrococcal nuclease activity by making the divalent salt inaccessible is contacting a pre-treated sample with egtazic acid (EGTA).
  • EGTA functions as a calcium chelator.
  • the set of pre-treatment components may further comprise a pH buffer to produce an optimal pH for the enzyme.
  • a pH buffer is Tris buffer.
  • the set of pre-treatment components may further comprise one or more components that improve stability of the enzyme in storage.
  • bovine serum albumin BSA
  • the set of pre-treatment mixture components comprises one or more of the components listed in Table 1.
  • the set of pre-treatment mixture components comprises the components listed in Table 1.
  • the set of pre-treatment mixture components comprises micrococcal nuclease and calcium chloride (CaCh).
  • the set of pre treatment mixture components comprises one or more of: (i) micrococcal nuclease, (ii) calcium chloride (CaCh): (iii) Tris buffer (e.g., Tris-HCl pH 8.8); and (iv) BSA.
  • the set of pre-treatment mixture components comprises (i) micrococcal nuclease, (ii) calcium chloride (CaCh); (iii) Tris buffer (e.g., Tris-HCl pH 8.8); and (iv) BSA.
  • the pre-treatment mixture further comprises sucrose.
  • the pre-treatment mixture further comprises dextran.
  • the pre-treatment mixture is lyophilized.
  • a lyophilized pre-treatment mixture is resuspended.
  • a lyophilized pre-treatment mixture may be resuspended with a liquid composition.
  • the lyophilized pre-treatment mixture may be resuspended with a sample or solution comprising target bacteria cells.
  • the concentration of one or more of the components of the pre-treatment mixture after resuspension is in the range of concentrations listed in Table 1.
  • the set of pre-treatment mixture components comprises the components listed in Table 1 and the concentration of each of the listed components after resuspension of the lyophilized pre-treatment mixture is in the range specified in Table 1.
  • the set of pre-treatment mixture components comprises one or more of the components listed in Table 2 and the concentration of each component after resuspension of the lyophilized pre-treatment mixture is the concentration listed in Table 2.
  • the set of pre-treatment mixture components comprises the components listed in Table 2 and the concentration of each of the listed components after resuspension of the lyophilized pre-treatment mixture is the concentration listed in Table 2.
  • the mechanism to inactivate micrococcal nuclease is addition of EGTA, a calcium chelator.
  • EGTA binds to calcium with high affinity, removing it from solution and making it inaccessible to micrococcal nuclease.
  • micrococcal nuclease can no longer cleave nucleic acids. This prevents the enzyme from removing potential target nucleic acids from intact cells collected in a sample.
  • the enzyme in the set of pre-treatment components cleaves nucleic acids at a temperature matching the lysis temperature of the cells in a sample. Such property of the enzyme will enable improved workflow efficiency for sample analysis.
  • a method of the present disclosure comprises contacting a provided sample or aliquot thereof with a pre-treatment mixture under conditions to remove nucleic acids not associated with intact cells in the sample or aliquot of the sample.
  • Methods of the present disclosure include cell lysis to release molecules, including nucleic acids such as DNA and RNA, from cells. Following release of nucleic acids, additional methods may be employed for processing the nucleic acids, including reverse transcription, amplification and/or detection of nucleic acids.
  • the provided lysis methods include advantages over other lysis methods, such advantages including ease of use, lytic efficiency and non-inhibitory properties to downstream methods such as helicase-dependent amplification (HD A).
  • compositions and methods to lyse bacterial cells may be used for lysing gram-negative bacteria and/or gram positive bacteria.
  • cell lysis compositions and methods of the disclosure are used for lysing gram-negative bacteria, such as Salmonella.
  • cell lysis compositions and methods of the disclosure are used for lysing gram positive bacteria, such as Listeria.
  • cell lysis compositions and methods of the disclosure are used for lysing both gram-negative bacteria and gram-positive bacteria.
  • Gram-negative bacteria, such as Salmonella can be lysed by only heating (e.g., to approximately 65°C-80°C).
  • Salmonella can be lysed with a water or buffer solution and heating to approximately 80°C for approximately 20 minutes.
  • Lysis components described by the present disclosure can be used to lyse both gram-negative bacteria and gram-positive bacteria.
  • Cell lysis comprises use of a lysis mixture comprising lysis mixture components.
  • the set of lysis mixture components comprises: (i) at least one lytic enzyme (for example, lysozyme and/or mutanolysin); (ii) at least one protease or enzyme that degrades protein (for example, proteinase K and/or achromopeptidase); (iii) a chelating resin; and (iv) a pH buffer (for example, Tris).
  • the chelating resin is Chelex®-100 resin (also referred to herein as simply “Chelex-100” or “Chelex”), which is identifiable by CAS number 11139- 85-8.
  • Chelex-100 is a styrene divinylbenzene copolymer containing paired iminodiacetate ions. Chelex-100 is an insoluble resin that chelates metals and divalent cations, and is known for lysing bacterial cells.
  • the pH buffer should be selected to produce an optimal pH for a downstream HDA method. In some embodiments, an optimal pH is a pH of about 8.8. While these components can be used to lyse gram-negative bacteria such as Salmonella, they are not necessary for Salmonella lysis, since as disclosed above, gram negative bacteria can be lysed by heating to approximately 80°C. These components do, however, enable lysis of gram-positive bacteria. Thus, the same lysis mixture described by the present disclosure can be used for gram-negative and gram-positive bacteria.
  • cell lysis described herein occurs after pre-treatment, such as the pre-treatment methods described above.
  • the set of lysis mixture components comprises a component to inactivate pre-treatment.
  • a component to inactivate pre-treatment is a divalent ion chelator.
  • divalent ion chelators include the following: EDTA, BAPTA and its derivatives (e.g., BAPTA-AM), EGTA derivatives (e.g., EGTA-AM), citric acid, FURA 2 and its derivatives, RHOD 2 and its derivatives, and FLUO 3 and its derivatives.
  • EGTA can inactivate pre-treatment.
  • the set of lysis mixture components comprises one or more of: (i) lyosozyme; (ii) mutanolysin; (iii) proteinase K; (iv) Chelex®-100; (v) Tris buffer; and (vi) EGTA.
  • the set of lysis mixture components comprises: (i) lyosozyme; (ii) mutanolysin; (iii) proteinase K; (iv) Chelex®-! 00; (v) Tris buffer; and (vi) EGTA.
  • the set of lysis mixture components further comprises sucrose.
  • the set of lysis mixture components further comprises dextran.
  • the set of lysis mixture components comprises one or more of: (i) lyosozyme; (ii) mutanolysin; (iii) proteinase K; (iv) achromopeptidase; (v) Chelex®- 100; (vi) Tris buffer; and (vii) EGTA.
  • the set of lysis mixture components comprises: (i) lyosozyme; (ii) mutanolysin; (iii) proteinase K; (iv) achromopeptidase; (v) Chelex®-100; (vi) Tris buffer; and (vii) EGTA.
  • the set of lysis mixture components further comprises sucrose.
  • the set of lysis mixture components further comprises dextran.
  • the lysis mixture is lyophilized. In some embodiments, one or more components of the lysis mixture are lyophilized together as one lyophilized pellet. In some embodiments, one or more components of the lysis mixture are lyophilized separately as more than one lyophilized pellet.
  • a first set of lysis mixture components comprising at least one lytic enzyme (for example, lysozyme and/or mutanolysin) and at least one protease or enzyme that degrades protein (for example, proteinase K and/or achromopeptidase) may be lyophilized as a first pellet and a second set of lysis mixture components comprising a chelating resin (for example, Chelex-100) may be lyophilized as a second pellet.
  • a chelating resin for example, Chelex-100
  • one or more lyophilized pellets each comprising one or more components of a lysis mixture are resuspended.
  • the one or more lyophilized pellets may be resuspended with a liquid composition.
  • the one or more lyophilized pellets may be resuspended with a sample or solution comprising target bacteria cells.
  • the one or more lyophilized pellets may be resuspended with an aliquot of a sample that has been pre-treated according to pre-treatment methods described above.
  • the concentration of one or more of the components of the lysis mixture after resuspension is in the range of concentrations listed in Table 3.
  • the set of lysis mixture components comprises the components listed in Table 3 and the concentration of each of the listed components after resuspension of the lyophilized lysis mixture components is in the range specified in Table 3.
  • the set of lysis mixture components comprises one or more of the components listed in Table 4 and the concentration of each component after resuspension of the lyophilized lysis mixture components is the concentration listed in Table 4.
  • the set of lysis mixture components comprises the components listed in Table 4 and the concentration of each of the listed components after resuspension of the lyophilized lysis mixture components is the concentration listed in Table 4.
  • a lysis mixture may also be referred to herein as a “lysis buffer”.
  • a method of the present disclosure comprises contacting an aliquot of a provided sample (e.g., environmental sample) with a lysis mixture (or lysis mixture components) under conditions to lyse at least a portion of cells in the aliquot, thereby generating a lysate.
  • a provided sample e.g., environmental sample
  • a lysis mixture or lysis mixture components
  • the entire collected sample is subjected to the lysis procedure, which is conducted in a small volume of lysis buffer.
  • a method of the present disclosure comprises a step of pre treating an aliquot of a provided sample (e.g., environmental sample) to remove nucleic acids not associated with intact cells, thereby generating a pre-treated aliquot, and contacting some or all of the pre-treated aliquot with the lysis mixture (or lysis mixture components) under conditions to lyse at least a portion of cells in the some or all of the pre-treated aliquot, thereby generating a lysate.
  • a provided sample e.g., environmental sample
  • the provided lysis compositions and methods can be used with downstream methods such as reverse transcription, helicase-dependent amplification (HD A), and/or nucleic acid detection methods.
  • downstream methods such as reverse transcription, helicase-dependent amplification (HD A), and/or nucleic acid detection methods.
  • the present disclosure provides cell lysis compositions and methods that can be used with downstream methods for detection of target nucleic acids.
  • the provided lysis compositions and methods can be used with downstream methods for determining the presence or absence of target bacteria in an environmental sample.
  • a sample comprising lysed cells is used in a downstream method, such as HD A.
  • a downstream method such as HD A.
  • the lysis methods of the present disclosure provide the advantages of improved limit of detection and improved sensitivity of downstream assays that measure target nucleic acid presence and/or levels as compared to other lysis methods.
  • Other lysis methods include lysis protocols for samples that are target-rich. For instance, other methods use clinical samples, such as throat swabs of patients, which contain many bacteria.
  • Target-rich samples allow use of lysis methods that have low lytic efficiency, such as lysis in which only 10% of bacteria in a sample is lysed and yet still enable detection of the target with an assay due to the high amount of bacteria.
  • the present lysis method enables lysis of more bacterial cells.
  • lysis methods of the present disclosure enable lysis of at least 90% of cells in a sample.
  • lysis methods of the present disclosure enable lysis of nearly every cell in the sample.
  • the lysis method of the present disclosure enables a limit of detection of approximately 10-100 cells with downstream assays.
  • Another improvement of the present lysis methods provides for the elimination of harsh chemicals that need to be neutralized or diluted prior to a sample being added to or used for a downstream method, such as a detection assay. While other lysis methods use such harsh chemicals, the lysis method disclosed herein does not use chemicals that require neutralization or dilution prior to target detection. The present lysis method thus improves workflow by minimizing touchpoints and minimizing steps from sample collection through analysis. Helicase-dependent amplification
  • HD A Helicase-dependent amplification
  • helicase(s) is a method for nucleic acid amplification that mimics an in vivo process of DNA replication, using helicase(s) to isothermally unwind nucleic acid duplexes. The resulting separated strands of the nucleic acid duplex provide templates for nucleic acid amplification.
  • the platform technology for HDA is described in U.S. Patent No. 7,282,328, ‘ leliease dependent amplification of nucleic acids,” which is incorporated by reference herein in its entirety.
  • HDA uses one or more helicases.
  • the separated nucleic acid strands serve as single-stranded templates for in vitro amplification of nucleic acids.
  • Sequence-specific primers hybridize to the templates and are then extended by DNA polymerases to amplify an HDA target nucleic acid. This process repeats itself so that exponential amplification can be achieved at a single temperature.
  • thermostable helicase which is a helicase that is capable of unwinding double- stranded DNA under elevated temperatures (e.g., preferred reaction temperature above about 60°C), can be used in HDA.
  • thermostable helicases include UvrD-like helicases.
  • Tte UvrD helicase is a helicase from the thermophilic organism Thermoanaerohacter (engcongensis.
  • a helicase selected for use in HDA methodology is a thermostable helicase.
  • the helicase is a Tte-UvrD helicase.
  • Regions of nucleic acid strands that have been separated by one or more helicases can be amplified as part of HDA methodology.
  • One or more polymerases are used for amplification.
  • a DNA polymerase can be used for amplification.
  • a reverse transcriptase is used to first copy the RNA (or a region of the RNA) into a cDNA molecule and the cDNA is amplified by a DNA polymerase.
  • the DNA polymerase acts on the HDA target nucleic acid to extend the primers hybridized to the nucleic acid templates in the presence of dNTPs to form primer extension products complementary to the nucleotide sequence on the nucleic acid template.
  • DNA polymerases for HDA may be selected from polymerases lacking 5' to 3' exonuclease activity and which additionally may optionally lack 3'-5' exonuclease activity.
  • the polymerase used according to the present disclosure is a thermostable polymerase.
  • the polymerase is Gst Polymerase.
  • the polymerase is WarmStart Gst polymerase, which is a Gst polymerase that has been modified to function at about 45°C or higher.
  • the polymerase is Bst polymerase.
  • the polymerase is WarmStart Bst polymerase, which is a Bst polymerase that has been modified to function at about 45°C or higher.
  • HDA methods of the disclosure are also referred to as “thermostable helicase-dependent amplification” (tHDA).
  • tHDA is a type of HDA that uses a thermostable helicase and a thermostable polymerase.
  • the thermostable properties of the helicase and polymerase enable performing HDA at high temperatures (e.g., 45°C-75°C), which may increase the specificity of target nucleic acid amplification.
  • primers suitable for use in HDA are short synthetic oligonucleotides, for example, having a length of more than 10 nucleotides and less than 50 nucleotides.
  • Oligonucleotide primer design involves various parameters such as string-based alignment scores, melting temperature, primer length and GC content (Kampke et al., Bioinformatics 17:214-225 (2003)).
  • string-based alignment scores such as string-based alignment scores, melting temperature, primer length and GC content (Kampke et al., Bioinformatics 17:214-225 (2003)).
  • Another important factor is to decide the melting temperature of a primer for HDA reaction. The melting temperature of a primer is determined by the length and GC content of that oligonucleotide.
  • the melting temperature of a primer is about equal to 10° C higher than the temperature at which the hybridization and amplification will take place.
  • the melting temperature of a pair of primers designed for that reaction should be in a range between 65°
  • the melting temperature of primers according to the present disclosure is about 65 °C.
  • Each primer hybridizes to each end of the HDA target nucleic acid and may be extended in a 5’ to 3’ direction by a polymerase using the target nucleotide sequence (or complementary sequence) as a template.
  • a homologous or perfect match primer is preferred.
  • primers may include sequences at the 5' end which are non-complementary to the target nucleotide sequence(s).
  • primers may contain nucleotides or sequences throughout that are not exactly complementary to the HDA target nucleic acid.
  • Primers may represent analogous primers or may be non-specific or universal primers for use in HDA as long as specific hybridization can be achieved by the primer-template binding at a predetermined temperature.
  • HDA methods may include more than one pair of primers. HDA methods using more than one pair of primers may be used to amplify nucleic acids comprising different target sequences of HDA.
  • HDA methods may also use single stranded binding proteins (SSB).
  • SSB single stranded binding proteins
  • Some helicases show improved activity in the presence of SSB, which can stabilize unwound single-stranded nucleic acids so that they do not re-anneal.
  • the presence of a single stranded binding protein is optional.
  • HDA methods may also use one or more accessory proteins.
  • the term “accessory protein” refers to any protein capable of stimulating helicase activity.
  • E. coli MutL protein is an accessory protein for enhancing UvrD helicase melting activity.
  • accessory proteins are desirable for use with selected helicases.
  • unwinding of nucleic acids may be achieved by helicases in the absence of accessory proteins.
  • HDA high-density polystyrene
  • buffers include one or more chemical reagents, one or more small molecules, salts (e.g., MgS04, KC1 and NaCl), additives, and/or excipients.
  • salts e.g., MgS04, KC1 and NaCl
  • excipients include sucrose, dextran and BSA.
  • components for HDA comprise one or more buffers, salts (e.g., MgSCri, KC1 andNaCl), additives, and/or excipients.
  • salts e.g., MgSCri, KC1 andNaCl
  • additives include Dithiothreitol (DTT) and Tween-20.
  • excipients include sucrose, dextran and BSA. Sucrose, dextran and BSA are inert components for lyophilization.
  • HDA occurs in the presence of a set of components comprising a helicase, an energy source, DNA polymerase, deoxynucleotide triphosphate (dNTPs) and primers.
  • an energy source are nucleotide triphosphates (NTPs) or dNTPs.
  • the set of components further comprise a single stranded binding protein.
  • An example of a single stranded binding protein is the thermophilic archaeal Sulfolobus solfataricus SSB (SSo-SSB).
  • the set of components further comprise a Tris buffer, MgSCfy KC1, NaCl, DTT, Tween-20, sucrose, dextran and BSA.
  • reverse transcription of RNA is combined with amplification of the resulting cDNA via HDA.
  • an initial target RNA in a provided sample is reverse transcribed to form target cDNA, and the target cDNA is amplified by HDA.
  • An illustrative non-limiting example of a method that combines reverse transcription of RNA with amplification of the resulting cDNA via HDA is shown in Figure 17 of U.S. Patent No. 7,662,594.
  • Methods of the present disclosure that combine reverse transcription and HDA include a reaction or a series of reactions that comprise reverse transcription, helicase-dependent denaturation and amplification.
  • Either a reverse transcriptase or a polymerase with reverse transcription properties can be used to synthesize cDNA by reverse transcription of target RNA.
  • Examples of reverse transcriptases include mutants of or wild-type Moloney Murine Leukemia Virus (MMLV) reverse transcriptase and mutants of or wild-type Avian Myeloblastosis Virus (AMV) reverse transcriptase.
  • MMLV Moloney Murine Leukemia Virus
  • AMV Avian Myeloblastosis Virus
  • a reverse transcriptase used according to the present disclosure is a mutant of the MMLV reverse transcriptase referred to as NxtScript Reverse Transcriptase (Roche Custom Biotech).
  • methods for detecting target bacteria combine reverse transcription of a target RNA with amplification of the resulting cDNA.
  • reverse transcription and DNA amplification occur at the same time and in the same reaction vessel.
  • a first strand cDNA is synthesized by reverse transcription of the target RNA, forming a DNA/RNA duplex.
  • a helicase unwinds the DNA/RNA duplex into at least partial single strand nucleic acids and a SSB stabilizes the single strand nucleic acids.
  • the single-stranded RNA enters a next round of reverse transcription (RT) reaction, generating more first strand cDNA.
  • RT reverse transcription
  • a pair of sequence-specific primers is used for the reverse transcription and amplification reactions.
  • a pair of sequence-specific primers one hybridizing to the 3’ end of the target nucleic acid (e.g., the target RNA, such as the 23 S rRNA) and the other hybridizing to the 3’ end of the complimentary strand which is produced by reverse transcription (i.e., the target cDNA), are used. Subsequently, the pair of primers hybridize to the analogous strands in the amplified products.
  • a pair of primers selected for HDA methods of the present disclosure are the primer pairs described above and in Example 1.
  • a pair of primers selected for HDA methods comprise nucleic acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3.
  • a pair of primers selected for HDA methods consist of nucleic acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3.
  • reverse transcription and HDA reactions occur in a single reaction vessel with a single buffer, such that cDNA copies of the RNA target sequence act as a template for DNA amplification at the same time as more cDNA is generated from RNA by reverse transcription.
  • Helicases that unwind both RNA-DNA duplexes and DNA duplexes are preferred in reactions that occur in a single reaction vessel.
  • a helicase can be, for example, Tte-UvrD helicase.
  • reverse transcription and amplification are performed isothermally. An advantage of these embodiments is that unwinding by helicase and amplification can effectively occur at a single temperature.
  • Methods of the present disclosure that combine reverse transcription and HDA can be used to detect and/or quantify target bacteria using HDA methodology.
  • reverse transcription and HDA occur in the presence of a set of components comprising a helicase, an energy source, DNA polymerase, reverse transcriptase, dNTPs and primers.
  • the set of components further comprise a single stranded binding protein.
  • the set of components further comprise a Tris buffer, MgSCri, KC1, NaCl, DTT, Tween-20, sucrose, dextran and BSA.
  • HDA Amplicon contamination control for helicase-dependent amplification
  • HDA compositions e.g., mixtures comprising HDA components
  • HDA methods are modified to incorporate components and/or methods for amplicon control.
  • amplicon control refers to reducing or eliminating carryover contamination. Amplicon control helps prevent prior positive reactions from contaminating and triggering false positives on subsequent negative reactions.
  • amplicon control involves a reaction that occurs before reverse transcription and amplification reactions described herein. Such an amplicon control reaction destroys or removes contamination amplicon. In some embodiments, an amplicon control reaction involves at least two enzymes that enable destruction of contamination amplicon.
  • an amplicon control reaction occurs in the same tube as HDA. In some embodiments, an amplicon control reaction must not occur during DNA amplification as it would destroy any amplified target (amplicon).
  • an amplicon control reaction occurs at a different temperature as HDA. In some embodiments, an amplicon control reaction requires a temperature of about 37°C. In some embodiments, one or more enzymes involved in amplicon control have to be inactivated at the reverse transcription and amplification step of HDA (about 65°C). In some embodiments, at least one enzyme involved in amplicon control is inactivated at temperatures higher than about 50°C.
  • components for amplicon control comprise: (i) an enzyme that binds uracil in a DNA strand and converts it into an apurinic site; (ii) an enzyme that cleaves DNA at apurinic sites; and (iii) a specialized dNTP that is recognized by the enzyme of (i).
  • components for amplicon control comprise: (i) uracil DNA glycosylase (also referred to as “UDG” or “UNG”); (ii) Endonuclease VIII; and (iii) dUTP.
  • the UDG is a thermolabile UDG.
  • a non-limiting example of a UDG that may be used as described herein is Antarctic Thermolabile UDG enzyme (New England Biolabs, Ipswich, MA).
  • dUTP is incorporated into all amplicons in an HDA method by Gst polymerase. As disclosed herein, the inclusion of dUTP does not inhibit Gst polymerase or the reverse transcriptase.
  • the concentration of dUTP should be optimized to sufficiently remove unwanted amplicon without slowing the reaction significantly.
  • Various methods and instruments can be used to detect and/or quantify target nucleic acids in conjunction with other methods of the present disclosure.
  • “to detect” means to identify the presence or absence of the target nucleic acids and “to quantify” means to measure or calculate the quantity of the target nucleic acids.
  • detection and quantification occur concomitantly. In some embodiments, detection and quantification are achieved by the same means.
  • detection and/or quantification comprises identifying and/or measuring amplified nucleic acids, for example, the amplicon products of HDA.
  • Amplified nucleic acid products may be identified and/or measured by methods including ethidium-bromide staining or by means of a label selected from the group consisting of a radiolabel, a fluorescent label, and an enzyme.
  • Fluorescence measurement is a type of detection/quantification method that can be used for detection and/or quantification of amplified nucleic acids of the present disclosure.
  • a fluorescent intercalator that is only fluorescent when bound to dsDNA, may be used for fluorescence measurement.
  • fluorescent probes may be designed to only fluoresce when bound to specific nucleic acid sequences, rather than any dsDNA.
  • amplified target nucleic acids can be detected/quantified using quenched fluorescent oligonucleotides that generate fluorescence when bound to or incorporated into an amplification product. Fluorescence can be measured using an instrument called a fluorometer.
  • Real-time measurement of nucleic acid amplification is also a type of detection/quantification method.
  • the progress of nucleic acid amplification is monitored as it occurs (i.e., in real time). Measurements are therefore collected throughout the process of amplification, rather than at the end of amplification.
  • Many real-time methods use fluorescence as the readout for nucleic acid amplification. Real time reactions are characterized by the point in time during cycling when amplification of a target is first detected rather than the amount of target accumulated after a fixed number of amplification cycles. The higher the starting copy number of the nucleic acid target, the sooner a significant increase in signal (e.g, fluorescence) is observed.
  • an endpoint assay measures the amount of accumulated product at the end of the amplification.
  • real-time measurement of nucleic acid amplification is used for detection and/or quantification of a target nucleic acid.
  • real time measurement is used to detect the amplicon products of HD A methods of the disclosure.
  • the step of detecting according to a method of the present disclosure comprises real-time measurement of amplified target cDNA.
  • detection and/or quantification comprises identifying and/or measuring the amplicon products of HD A.
  • detection and/or quantification of the amplicon products of HD A comprises subjecting the assay mixture to successive cycles of amplification to generate a signal from a probe designed to detect the amplicon (for example, a fluorescent signal) and quantifying the nucleic acid presence.
  • quantifying the nucleic acid presence is based on the signal cycle threshold of the amplification reaction.
  • the step of detecting according to a method of the present disclosure comprises quantifying the presence of amplified target cDNA based on a fluorescence signal cycle threshold of the amplification reaction.
  • quantifying the nucleic acid presence is based on the strength of a detection signal.
  • the step of detecting presence or absence of amplified target cDNA according to a method of the present disclosure comprises determining fluorescence signal from a fluorescent molecular probe as an indication of presence based on the speed of the signal. In some embodiments, the step of detecting further comprises determining fluorescence signal from the probe as an indication of presence based on the rate at which signal increases and the strength of the signal.
  • the step of detecting presence or absence of the amplified target cDNA comprises: (i) detecting the speed of the signal and the strength of the signal that meets a threshold speed and strength and thereby determining the presence of the target bacteria in a sample (e.g., environmental sample); or (ii) detecting that the speed of the signal arid the strength of the signal does not meet a threshold speed and strength and thereby determining the absence of the target bacteria in the sample.
  • a sample e.g., environmental sample
  • an algorithm is used for detection and/or quantification.
  • a molecular probe e.g., a fluorescent molecular probe
  • an algorithm can be used to determine signal from the probe as an indication of presence based on the speed of the signal, as determined by the Cq (when fluorescence intensity exceeds a noise threshold) and the slope (the rate at which fluorescence increases), and the strength of the signal (maximum fluorescence). If the generated signal meets the threshold speed and strength criteria, it will be called “present” (positive signal).
  • the speed of the signal and the strength of the signal is considered to meet the threshold speed and strength criteria if it matches or surpasses the threshold values set for speed and strength.
  • a speed signal is considered to match or surpass the threshold value set for speed if it exceeds a noise threshold at or before the speed threshold value
  • a strength signal is considered to match or surpass the threshold value set for strength if the maximum fluorescence matches or surpasses the strength threshold value.
  • the presence and absence assay signal are reliant on the limit of detection of the assay.
  • Samples with a target concentration for example, the concentration of Salmonella rRNA prior to reverse transcription and amplification
  • a target concentration for example, the concentration of Salmonella rRNA prior to reverse transcription and amplification
  • an absence signal does not mean an absolute absence of the target. Usually multiple replicates are necessary to detect presence at these levels.
  • Amplification assay results may be read by an automated reader, such as a reader that measure fluorescence. Alternatively or additionally, assay results may be detected by enzymatic detection methods or gel electrophoresis.
  • detection of amplified nucleic acids comprises quantification of the amplified product (e.g., quantification of the amplicon).
  • quantification comprises measuring relative levels of a readout, such as relative levels of a test readout (e.g., a readout indicating presence of a target nucleic acid) relative to a control readout.
  • the readout is a fluorescence readout.
  • detection of amplified nucleic acids comprises detecting presence or absence of the amplified product.
  • the amplicon comprises the nucleic acid sequence (read in the 5’ to 3’ direction) of GAG AAG GCA CGC TGA CAC GTA GGT GAA GTG ATT TAC TCA CGG AGC TGA AGT CAG (SEQ ID NO: 4).
  • the amplicon comprises a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% but less than 100% sequence identity to SEQ ID NO: 4.
  • the amplicon consists of the nucleic acid sequence of SEQ ID NO: 4.
  • one or more target nucleic acids are amplified according to HDA methods and the amplified nucleic acid is detected using a probe designed to identify the amplified nucleic acid.
  • an initial target RNA present in a provided sample is reverse transcribed to form target cDNA, the target cDNA is amplified by HDA, and the amplified target cDNA is detected.
  • the probe used to detect amplified nucleic acids of the present disclosure is a fluorescent hybridization probe.
  • the fluorescent hybridization probe is a conditional fluorescent hybridization probe that emits fluorescence when hybridized to a nucleic acid molecule.
  • a conditional fluorescent hybridization probe comprises a fluorophore and a quencher that prevents the fluorophore from generating fluorescence unless the probe is bound to the amplified nucleic acid being detected.
  • the conditional fluorescent hybridization probe comprises the nucleic acid sequence of: CCA TGA GTA AAT rCAC TTC ACC TAC GTG (SEQ ID NO: 5), wherein the “r” denotes that the base is RNA.
  • the conditional fluorescent hybridization probe comprises a nucleic acid sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • a fluorophore may be linked at either the 5’ or 3’ end of the probe.
  • a quencher may be linked at the opposite end of the probe to that of the fluorophore.
  • the conditional fluorescent hybridization probe comprises 5’ /56-ROXN/ CCA TGA GTA AAT rCAC TTC ACC TAC GTG /3IAbRQSp/ 3’ (also referred to by the present disclosure as the “Sal ROX probe”), wherein “56-ROXN” is ROX (carboxy-X-rhodamine) fluorophore; “3IAbRQSp” is Iowa Black RQ-Sp Quencher; and the “r” denotes that the base is RNA.
  • This probe comprises DNA bases and a single RNA base. When the probe binds the nucleic acid being detected, the RNA base can be recognized by an enzyme (e.g., RNase H2) that cleaves the probe, thereby separating the quencher and the fluorophore and generating fluorescence.
  • an enzyme e.g., RNase H2
  • detection of amplified nucleic acid occurs in the same reaction vessel as nucleic acid amplification. In some embodiments, detection of amplified nucleic acid occurs in the same reaction vessel as reverse transcription of an initial target RNA to form target cDNA and amplification by HDA of the target cDNA; in this scenario, the nucleic acid being detected is the amplified cDNA. In some embodiments, the amplified cDNA is detected/quantified using an instrument that supports isothermal DNA/RNA amplification methods. In some embodiments, the instrument takes fluorescence measurements in real-time. As non-limiting examples, the instrument may be a Genie® II or Genie® III reader (made by OptiGene, UK). In some embodiments, the instrument used according to methods of the present disclosure is a Genie® II reader (OptiGene, UK).
  • detection of amplified nucleic acid comprises use of a detection mixture comprising a set of detection mixture components.
  • the set of detection mixture components comprises a probe.
  • the probe is a conditional fluorescent hybridization probe.
  • the conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising the nucleic acid sequence of: CAC GTA GGT GAA GTG ATT TAC TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6.
  • conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 6. In some embodiments, the conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising a nucleic acid sequence having 100% sequence identity to SEQ ID NO: 6.
  • the conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising the nucleic acid sequence of: CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7. In some embodiments, the conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising a nucleic acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 7. In some embodiments, the conditional fluorescent hybridization probe emits fluorescence when hybridized to a nucleic acid molecule comprising a nucleic acid sequence having 100% sequence identity to SEQ ID NO: 7.
  • the set of detection mixture components comprises a Sal ROX probe and RNase H2.
  • the set of detection mixture components further comprises any of the HDA components described above.
  • the set of detection mixture components comprises components for HDA and reverse transcription.
  • the set of detection mixture components further comprises components for amplicon control, such as the components described above.
  • the set of detection mixture components comprises one or more of: a Sal ROX probe, RNase H2, a helicase, an energy source, DNA polymerase, reverse transcriptase, dNTPs and primers.
  • the set of detection mixture components comprises a Sal ROX probe, RNase H2, a helicase, an energy source, DNA polymerase, reverse transcriptase, dNTPs and primers.
  • the set of components further comprises a single stranded binding protein.
  • the set of components further comprises a UDG, an enzyme that cleaves DNA at apurinic sites, and dUTP.
  • the set of components further comprises a Tris buffer, MgS0 4 , KC1, NaCl, DTT, Tween-20, sucrose, dextran and/or BSA.
  • the primers of a detection mixture comprise a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of the target RNA and a second primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the target RNA sequence.
  • the set of detection mixture components further comprises a control RNA and a control probe that is able to detect the control RNA.
  • the control probe is able to detect amplification products of the control RNA.
  • amplification products of the control RNA are amplified by the same primers as those used for reverse transcription and HDA in the detection mixture.
  • the detection mixture is lyophilized.
  • a detection mixture contacted with a composition or mixture comprising a nucleic acid template for the nucleic acid to be detected by components in the detection mixture generates an assay mixture.
  • an “assay mixture” refers to a mixture comprising components of a detection mixture and a nucleic acid template for amplification of nucleic acids detected by the probe in the detection mixture.
  • the nucleic acid template is an RNA (or a region of the RNA) that is reverse transcribed in the assay mixture into a cDNA and the cDNA is amplified and detected by the probe.
  • an assay mixture is generated when a lysate or an aliquot of a lysate is contacted with a detection mixture.
  • a method of the present disclosure comprises reverse transcribing a target RNA of a target bacteria in the assay mixture to form target cDNA and amplifying the target cDNA by helicase-dependent amplification (HDA).
  • a method of the present disclosure also comprises detecting presence or absence of the amplified target cDNA, thereby determining the presence or absence of the target bacteria in the sample.
  • the present disclosure provides methods for detection of Salmonella spp. from environmental samples.
  • the present disclosure provides methods of detecting Salmonella from an environmental sample without the need for enrichment or a prolonged incubation period.
  • the provided methods for Salmonella detection combine various individual methods described above (e.g., pre-treatment, lysis, HDA, amplicon control and/or detection/quantification of target nucleic acids) for the purposes of detecting and/or quantifying Salmonella from a sample.
  • methods for detecting Salmonella combine reverse transcription of a target RNA with amplification of the resulting cDNA.
  • reverse transcription and DNA amplification occur at the same time and in the same reaction vessel. Descriptions of concurrent reverse transcription and DNA amplification are provided above, for example, in the “Helicase-dependent amplification” section.
  • the provided methods for detection of Salmonella also combine various other methods described throughout the present disclosure to detect and/or quantify Salmonella in a sample.
  • a non-limiting example of the combination of methods from the present disclosure that can be used for detection of Salmonella comprise: (i) combined reverse transcription and DNA amplification via thermostable helicase-dependent amplification (tHDA) and (ii) detection of amplified nucleic acids.
  • Another non-limiting example of the combination of methods from the present disclosure that can be used for detection of Salmonella comprise: (i) bacterial cell lysis; (ii) combined reverse transcription and DNA amplification via thermostable helicase-dependent amplification (tHDA); and (iii) detection of amplified nucleic acids.
  • Another non-limiting example of the combination of methods from the present disclosure that can be used for detection of Salmonella comprise: (i) sample pre-treatment to remove nucleic acids not associated with intact cells; (ii) bacterial cell lysis; (iii) combined reverse transcription and DNA amplification via thermostable helicase-dependent amplification (tHDA); and (iv) detection of amplified nucleic acids.
  • Another non-limiting example of the combination of methods from the present disclosure that can be used for detection of Salmonella comprise: (i) sample pre-treatment to remove nucleic acids not associated with intact cells; (ii) bacterial cell lysis; (iii) amplicon control to prevent prior positive reactions from contaminating and triggering false positives on subsequent negative reactions; (iv) combined reverse transcription and DNA amplification via thermostable helicase-dependent amplification (tHDA); and (v) detection of amplified nucleic acids.
  • detection of amplified nucleic acids comprises use of at least one fluorescent hybridization probe that recognizes the amplified nucleic acids.
  • nucleic acid amplification occurs at a single temperature (usually between about 55-68 °C). In some embodiments, nucleic acid amplification occurs at or above 45 °C and at or below 70 °C.
  • the combination of methods for detection of Salmonella comprises use of a pre-treatment mixture, a lysis mixture, and/or a detection mixture.
  • a pre-treatment mixture comprises: (i) micrococcal nuclease, (ii) CaCh; (iii) Tris-HCl, pH 8.8 (iv) BSA; (v) dextran; and (vi) sucrose.
  • the pre-treatment mixture is lyophilized.
  • the set of pre treatment mixture components comprises the components listed in Table 2 and the concentration of each of the listed components after resuspension of the lyophilized pre treatment mixture is the concentration listed in Table 2.
  • the lysis mixture comprises: (i) lyosozyme; (ii) mutanolysin; (iii) proteinase K; (iv) achromopeptidase; (v) Chelex®-100; (vi) Tris HC1, pH 8.8; (vii) EGTA; (viii) dextran; and (ix) sucrose.
  • the lysis mixture components are lyophilized as one or more lyophilized pellets.
  • the set of lysis mixture components comprises the components listed in Table 4 and the concentration of each of the listed components after resuspension of the lyophilized lysis mixture components is the concentration listed in Table 4.
  • the detection mixture comprises: (i) a Sal ROX probe, (ii) RNase H2, (iii) a helicase, (iv) an energy source in the form of dATP, (v) DNA polymerase, (vi) reverse transcriptase, (vii) dNTPs, (viii) forward and reverse primers, (ix) Tris-HCl, pH 8.8, (x) KC1, (xi) NaCl, and (xii) magnesium sulfate.
  • the detection mixture further comprises at least one single stranded binding protein (SSB).
  • SSB single stranded binding protein
  • the detection mixture further comprises: (i) UDG, (ii) Endonuclease VIII, and (iii) dUTP. In some embodiments, the detection mixture further comprises: (i) DTT, (ii) Tween-20, (iii) sucrose, (iv) dextran, and/or (v) BSA. In some embodiments, the detection mixture further comprises a control RNA and a control probe that is able to detect the control RNA. In some embodiments, the detection mixture comprises one or more of the components listed in Table 5. In some embodiments, one or more components of the detection mixture are lyophilized together as one lyophilized pellet. In some embodiments, one or more components of the detection mixture are lyophilized separately as more than one lyophilized pellet.
  • the forward and revers primers of a detection mixture comprise a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of the target RNA and a second primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the target RNA sequence.
  • the detection mixture is lyophilized.
  • one or more lyophilized pellets, each comprising one or more components of a detection mixture are resuspended.
  • the one or more lyophilized pellets may be resuspended with a liquid composition.
  • the one or more lyophilized pellets may be resuspended with a sample or solution comprising lysed target bacteria cells (e.g., a lysate or an aliquot thereof).
  • the concentration of one or more of the components of the detection mixture after resuspension is in the range of concentrations listed in Table 5.
  • the set of detection mixture components comprises the components listed in Table 5 and the concentration of each of the listed components after resuspension of the lyophilized detection mixture components is in the range specified in Table 5. In some embodiments, the set of detection mixture components comprises one or more of the components listed in Table 6 and the concentration of each component after resuspension of the lyophilized detection mixture components is the concentration listed in Table 6. In some embodiments, the set of detection mixture components comprises the components listed in Table 6 and the concentration of each of the listed components after resuspension of the lyophilized detection mixture components is the concentration listed in Table 6.
  • the forward primer of the detection mixture comprises the nucleic acid sequence of 5’ GAG AAG GCA CGC TGA CAC 3’(SEQ ID NO: 2) and the reverse primer comprises the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3).
  • methods for detecting Salmonella provided herein comprise determining the presence or absence of Salmonella in an environmental sample.
  • the environmental sample is from an environment comprising a low concentration of Salmonella and the methods described herein are of sufficient sensitivity to detect the presence of Salmonella in the environmental sample.
  • methods described herein are of sufficient sensitivity to detect presence of Salmonella from a sample having as little as 30-60 CFU of Salmonella. In some embodiments, methods described herein are of sufficient sensitivity to detect presence of Salmonella from a sample having as little as 5-10 CFU of Salmonella. In some embodiments, the sample further comprises bacteria that is not Salmonella. In some embodiments, the environmental sample is from a solid surface comprising a low concentration of Salmonella and the methods described herein are of sufficient sensitivity to detect the presence of Salmonella in the environmental sample. In some embodiments, methods described herein are of sufficient sensitivity to detect presence of Salmonella in an environmental sample from a solid surface that comprises from about 5 to about 200 CFU of Salmonella per 1 square inch of the solid surface.
  • the solid surface comprises from about 5 to about 100 CFU of Salmonella per 1 square inch of the solid surface. In some embodiments, the solid surface comprises from about 5 to about 50 CFU of Salmonella per 1 square inch of the solid surface. In some embodiments, the solid surface further comprises microflora that is not Salmonella. In various embodiments wherein the sample or environment from where the sample is collected comprises Salmonella and microflora that is not Salmonella, the methods described herein are of sufficient sensitivity and specificity to detect presence of Salmonella.
  • compositions and kits that may be used in the methods described herein.
  • the disclosure provides a lyophilized pre-treatment composition comprising one or more components of a pre-treatment mixture.
  • the lyophilized pre-treatment composition comprises (i) micrococcal nuclease, (ii) calcium chloride (CaCh); (iii) Tris buffer (e.g., Tris-HCl pH 8.8); and (iv) BSA.
  • the lyophilized pre-treatment composition further comprises sucrose.
  • the lyophilized pre-treatment composition further comprises dextran.
  • the concentration of each component of the lyophilized pre-treatment composition after resuspension is the concentration listed in Table 2.
  • the present disclosure provides a lyophibzed composition comprising micrococcal nuclease and calcium chloride (CaCh), wherein, upon resuspension of the lyophilized composition, the concentration of micrococcal nuclease ranges from 0.1- 0.3 Units/pL and the concentration of CaCh ranges from 2-6 mM. In some embodiments, upon resuspension of the lyophilized composition, the concentration of micrococcal nuclease is 0.22 Units/pL and the concentration of CaCh is 4.1 mM.
  • CaCh calcium chloride
  • the disclosure provides a lyophilized lysis composition comprising one or more components of a lysis mixture.
  • the lyophilized lysis composition comprises (i) at least one of lyosozyme and mutanolysin; (ii) at least one of proteinase K and achromopeptidase; and (iii) EGTA.
  • the concentration of each component of the lyophilized lysis composition after resuspension is the concentration listed in Table 4.
  • the present disclosure provides a lyophilized composition
  • a lyophilized composition comprising (i) at least one of lyosozyme and mutanolysin; (ii) at least one of proteinase K and achromopeptidase; and (iii) EGTA, wherein, upon resuspension of the lyophilized composition, the concentration of lysozyme ranges from 0-1 mg/mL, the concentration of mutanolysin ranges from 0-30 Units/mL, the concentration of proteinase K ranges from 0-1 mg/mL, the concentration of achromopeptidase ranges from 0-150 Units/mL, and the concentration of EGTA ranges from 2-5 mM.
  • the concentration of lysozyme is 0.8 mg/mL
  • the concentration of mutanolysin is 20 Units/mL
  • the concentration of proteinase K is 0.8 mg/mL
  • the concentration of achromopeptidase is 85.6 Units/mL
  • the concentration of EGTA is 2.6 mM.
  • the disclosure provides a lyophilized detection mixture composition comprising one or more components of a detection mixture.
  • the one or more components may be selected from components listed in Table 6.
  • the disclosure provides a lyophilized composition
  • a first primer comprising the nucleic acid sequence of CTG ACT TCA GCT CCG TGA GTA AAT (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3
  • a second primer comprising the nucleic acid sequence of GAG AAG GCA CGC TGA CAC (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • kits comprising components and/or compositions used in the methods described herein.
  • kits of the present disclosure may be for use in a method of determining the presence or absence of target bacteria in an environmental sample.
  • a kit may comprise one or more of: a collection device, pre treatment mixture or components thereof, lysis mixture or components thereof, detection mixture or components thereof, equipment (e.g., optical reader), reagents (primers, probes, dNTPs, enzymes, etc.), and instructions for use.
  • equipment e.g., optical reader
  • reagents primers, probes, dNTPs, enzymes, etc.
  • a kit comprises a pre-treatment mixture, a lysis mixture, and a detection mixture.
  • one or more of the pre-treatment mixture, the lysis mixture, and the detection mixture are lyophilized.
  • one or more components of the pre-treatment mixture, the lysis mixture, and the detection mixture are lyophilized.
  • a kit comprises a first mixture and a second mixture, wherein the first mixture comprises micrococcal nuclease and a divalent salt and the second mixture comprises a divalent ion chelator, at least one lytic enzyme and at least one protease.
  • the divalent salt may be calcium chloride (CaCh) and the divalent ion chelator may be EGTA.
  • the at least one lytic enzyme comprises lyosozyme and mutanolysin and the at least one protease is proteinase K.
  • the kit further comprises a third mixture, the third mixture comprising a chelating resin such as Chelex-100.
  • the kit further comprises a fourth mixture, the fourth mixture comprising a helicase, an energy source for the helicase, a DNA polymerase, a reverse transcriptase, and dNTPs.
  • the fourth mixture further comprises a single stranded binding protein.
  • the fourth mixture further comprises (i) an enzyme that binds uracil in a DNA strand and converts it into an apurinic site; (ii) an enzyme that cleaves DNA at apurinic sites; and (iii) a specialized dNTP that is recognized by the enzyme of (i).
  • the fourth mixture further comprises a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of the Salmonella 23 S ribosomal RNA and a second primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the nucleic acid sequence of the Salmonella 23S ribosomal RNA.
  • the first primer may comprise the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3 and the second primer may comprise the nucleic acid sequence of 5’ GAG AAG GCA CGC TGA CAC 3’ (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the fourth mixture further comprises at least one probe.
  • the at least one probe may be a conditional fluorescent hybridization probe that emits fluorescence when hybridized to a nucleic acid molecule comprising the nucleic acid sequence of: (i) CAC GTA GGT GAA GTG ATT TAC TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6; or (ii) CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7.
  • the at least one probe comprises the nucleic acid sequence of: CCA TGA GTA AAT rCAC TTC ACC TAC GTG (SEQ ID NO: 5), or a sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • the first, second, third and/or fourth mixture is lyophilized.
  • the first mixture is lyophilized and upon resuspension of the first mixture, the concentration of micrococcal nuclease ranges from 0.1-0.3 Units/pL and the concentration of the divalent salt ranges from 2-6 mM.
  • the second mixture is lyophilized and upon resuspension of the second mixture, the concentration of the divalent ion chelator ranges from 2-5 mM.
  • a kit provided by the present disclosure comprises a first primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence of Salmonella 23 S ribosomal RNA and a second primer having hybridization specificity for a single-stranded nucleic acid region comprising a nucleic acid sequence complementary to the nucleic acid sequence of the Salmonella 23S ribosomal RNA.
  • the first primer comprises the nucleic acid sequence of 5’ CTG ACT TCA GCT CCG TGA GTA AAT 3’ (SEQ ID NO: 3) or a sequence with at least 90% sequence identity to SEQ ID NO: 3 and the second primer comprises the nucleic acid sequence of 5’ GAG AAG GCA CGC TGA CAC 3’ (SEQ ID NO: 2) or a sequence with at least 90% sequence identity to SEQ ID NO: 2.
  • the kit further comprises at least one probe for detecting a nucleic acid molecule comprising the nucleic acid sequence of: (i) CAC GTA GGT GAA GTG ATT TAC TCA CGG (SEQ ID NO: 6), or a sequence with at least 90% sequence identity to SEQ ID NO: 6; or (ii) (ii) CAC GTA GGT GAA GTG ATT TAC TCA TGG (SEQ ID NO: 7), or a sequence with at least 90% sequence identity to SEQ ID NO: 7.
  • the kit comprises at least one probe that comprises the nucleic acid sequence of: CCA TGA GTA AAT rCAC TTC ACC TAC GTG (SEQ ID NO: 5), or a sequence with at least 90% sequence identity to SEQ ID NO: 5.
  • the first primer, the second primer and the probe are lyophilized.
  • Example 1 Design of primers and probe for amplification and detection of Salmonella target nucleic acids
  • the present example demonstrates methods for the design of primers and probes to amplify and detect nucleic acids from Salmonella species (spp.).
  • the primers and probes designed according to the present example are specific to Salmonella enterica subspecies and serovars and are not specific to other bacteria such as Escherichia coli ( E . coli).
  • RNA sequences for bacteria of interest Salmonella spp.
  • other bacteria e.g., Salmonella spp.
  • E. coli, C. freundii were obtained from the National Center for Biotechnology Information (NCBI) GenBank and aligned using DNASTAR (Madison, WI) software. Forward and reverse primers and a probe were designed against Salmonella 23 S rRNA sequence. The primers were designed to match tHDA primer design parameters and they were ordered from Integrated DNA Technologies (IDT) (Coralville, IA). Table 7 shows the sequences of the primers and probe.
  • Lysis and amplification of the samples were performed as follows, 100 pL of the desired dilutions were added to cluster tubes containing lyophilized pre-treatment mixture. The samples were incubated at 37°C for 10 minutes. The 100 pL of pre-treatment reaction was transferred to cluster tubes containing a lyophilized chelating resin (Chelex) mix. Then, 400 pL of lysis enzyme solution was added to the same tubes. Samples were vortexed at 2,500 rpm to mix and incubated at 37°C for 20 minutes. Samples were vortexed again at 2,500 rpm and incubated at 95°C for 8 minutes.
  • Table 13 provides the sequences of the control RNA and control HDA HEX probe referred to in Table 12.
  • the term “5HEX” in Table 13 represents 5’ Hexachlorofluorescein, a fluorophore attached to the 5’ end of the oligonucleotide.
  • the term “3BHQ 1” in Table 13 represents 3’ Black Hole Quencher, a quencher attached to the 3’ end of the oligonucleotide that can absorb the fluorescence from the fluorophore (HEX) while the probe is uncleaved. When the probe is cleaved, the quencher is not close enough to absorb fluorescence so the fluorophore’ s fluorescence can be detected.
  • the designed primer pairs and probe show good specificity and sensitivity for Salmonella detection.
  • the below additional examples illustrate Salmonella detection assays using these primers and probe.
  • the sponge was placed back into its original bag after sampling, 15 mL of Butterfield Phosphate Buffer (BPB) was added, the bag was stomached to detach the target cells into the liquid, the samples were concentrated by centrifugation at 5000 rpm for 10 minutes and the supernatant was discarded, the pellet was resuspended with 110 pL BPB, 100 pL of sample was transferred to pre-treatment tubes and the Salmonella detection assay procedures were followed.
  • BPB Butterfield Phosphate Buffer
  • the Salmonella detection assay procedures for the present example were as follows: (1) pipette 100 pL of sample into a tube with lyophilized pretreatment mixture (the lyophilized pre-treatment mixture comprises Tris-HCl, CaCf.
  • micrococcal nuclease BSA, sucrose and dextran
  • BSA micrococcal nuclease
  • dextran sucrose and dextran
  • vortex 2-3 seconds at half speed or 2,500 rpm incubate sample for 10 minutes at 37°C
  • pre-treatment step (4) rehydrate lysis components with 14 mL of resuspension buffer (the lysis components and resuspension buffer comprise Tris-HCl, sucrose, lysozyme, proteinase K, mutanolysin,
  • the Chelex tube comprises Chelex-100, sucrose, dextran, and Tris- HCl
  • Table 14 shows results for the swab collection method and Table 15 shows results for the sponge collection method.
  • Salmonella detection assay sensitivity with swab collection method Table 14. Salmonella detection assay sensitivity with sponge collection method
  • Example 3 Salmonella detection with delayed sample processing
  • the present example demonstrates that collected samples do not need to be processed immediately following collection. Instead, collected samples can be temporarily stored prior to the target bacteria detection assay.
  • Salmonella detection assay can be used to detect target bacteria in samples collected and stored prior to processing. Also as shown here, samples kept cold under refrigerated conditions can be tested within 24 hours.
  • Example 4 Salmonella environmental surface testing with swab collection
  • Plastic surfaces (1”X1”) were inoculated with S. Heidelberg and E. coli at 10 times higher as the background microflora. The surfaces were dried overnight at room temperature, and sampled with Letheen swabs. The Letheen swabs were tested by Salmonella detection assay according to the procedures outlined above in Example 2.
  • the reference culture method was also tested. The reference culture method included enrichment in 10 mL lactose broth at 35 °C for 24 hours and enrichment in 10 mL RV broth at 35 °C for 24 hours followed by streaking on a XLD agar plate for identifying typical Salmonella colonies. Results are shown in Table 17.
  • the reference culture method included enrichment in 225 mL lactose broth at 35 °C for 24 hours followed by streaking on a XLD agar plate for identifying typical Salmonella colonies. Results are shown in Table 18. Table 18. Stainless steel surface (4”X4”) with S. Heidelberg
  • the tHDA assay with pre-treatment is comparable to the conventional culture method in detecting Salmonella spp. on environmental surfaces.
  • Example 6 Salmonella detection from environmental surface samples without pre-treatment incubation
  • tHDA shows more positive results, as shown in Table 19.
  • the purpose of pre-treatment is to remove nucleic acids from lysed cells existing in the environment. Without pre-treatment, most free nucleic acids are not cleaved, therefore more positive results are observed.
  • Example 7 Alternative sample preparation protocol and detection of Salmonella target nucleic acids
  • the present example demonstrates an alternative method for preparing samples to detect nucleic acids from Salmonella species (spp.) without using pre-treatment, lysis enzymes, or chelating resin.
  • An overnight culture of Salmonella Typhimurium was prepared by growing it in Tryptic Soy Broth (TSB) at 37°C. The culture was serially diluted in Molecular-grade water to obtain the desired dilution. Immediately, 100 pL of the desired dilutions were plated on Tryptic Soy Agar (TSA) plates and incubated overnight at 37°C to obtain the titers for the overnight culture.
  • TSA Tryptic Soy Agar
  • Lysis and amplification of the samples were performed as follows, 100 pL of the desired dilutions were added to 1.5 mL micro-centrifuge tubes. 400 pL of Molecular-grade water was added to each dilution. No template controls (NTCs) substituted 100 pL of
  • the designed primer pairs and probe show good specificity and sensitivity for Salmonella detection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions, des procédés et des kits pour la détection de Salmonella à partir d'un échantillon environnemental, sans avoir besoin d'une étape d'enrichissement ou d'incubation prolongée.
PCT/US2021/025053 2021-03-31 2021-03-31 Détection de salmonella à partir d'un échantillon environnemental WO2022211796A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2021/025053 WO2022211796A1 (fr) 2021-03-31 2021-03-31 Détection de salmonella à partir d'un échantillon environnemental

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/025053 WO2022211796A1 (fr) 2021-03-31 2021-03-31 Détection de salmonella à partir d'un échantillon environnemental

Publications (2)

Publication Number Publication Date
WO2022211796A1 true WO2022211796A1 (fr) 2022-10-06
WO2022211796A8 WO2022211796A8 (fr) 2023-04-06

Family

ID=83459821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025053 WO2022211796A1 (fr) 2021-03-31 2021-03-31 Détection de salmonella à partir d'un échantillon environnemental

Country Status (1)

Country Link
WO (1) WO2022211796A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096937A1 (en) * 2002-01-30 2004-05-20 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
WO2005030027A2 (fr) * 2003-04-29 2005-04-07 The Cleveland Clinic Foundation Identification de detection de salmonella
US20060154286A1 (en) * 2002-09-20 2006-07-13 New England Biolabs, Inc. Helicase-dependent amplification of nucleic acids
US20150191778A1 (en) * 2011-04-19 2015-07-09 Life Technologies Corporation Compositions and methods for detecting and identifying salmonella enterica strains
US20150259728A1 (en) * 2013-07-21 2015-09-17 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20180179582A1 (en) * 2015-09-15 2018-06-28 Neogen Corporation Methods of Detecting Listeria from an Environmental Sample
US20190085377A1 (en) * 2015-07-22 2019-03-21 Ares Genetics Gmbh Genetic testing for predicting resistance of salmonella species against antimicrobial agents
WO2019084394A1 (fr) * 2017-10-27 2019-05-02 University Of Cincinnati Compositions, procédés et kits pour la digestion en une étape d'acide nucléique pour analyse par chromatographie en phase liquide-spectrométrie de masse en tandem

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096937A1 (en) * 2002-01-30 2004-05-20 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US20060154286A1 (en) * 2002-09-20 2006-07-13 New England Biolabs, Inc. Helicase-dependent amplification of nucleic acids
WO2005030027A2 (fr) * 2003-04-29 2005-04-07 The Cleveland Clinic Foundation Identification de detection de salmonella
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
US20150191778A1 (en) * 2011-04-19 2015-07-09 Life Technologies Corporation Compositions and methods for detecting and identifying salmonella enterica strains
US20150259728A1 (en) * 2013-07-21 2015-09-17 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20190085377A1 (en) * 2015-07-22 2019-03-21 Ares Genetics Gmbh Genetic testing for predicting resistance of salmonella species against antimicrobial agents
US20180179582A1 (en) * 2015-09-15 2018-06-28 Neogen Corporation Methods of Detecting Listeria from an Environmental Sample
WO2019084394A1 (fr) * 2017-10-27 2019-05-02 University Of Cincinnati Compositions, procédés et kits pour la digestion en une étape d'acide nucléique pour analyse par chromatographie en phase liquide-spectrométrie de masse en tandem

Also Published As

Publication number Publication date
WO2022211796A8 (fr) 2023-04-06

Similar Documents

Publication Publication Date Title
Dashti et al. Heat treatment of bacteria: a simple method of DNA extraction for molecular techniques
JP5684563B2 (ja) カルバペネマーゼ遺伝子の同定のための組成物および方法
US7662594B2 (en) Helicase-dependent amplification of RNA
JP6014649B2 (ja) 標的核酸配列の選択的ハイブリダイゼーションおよび捕捉における使用のため不活化可能型標的捕捉オリゴマー
KR102630602B1 (ko) 핵산 증폭의 저해를 감소시키는 조성물
DK2902506T3 (en) DETECTION OF LISTERIA SPECIES IN FOODS AND ENVIRONMENTAL TESTS, PROCEDURES AND COMPOSITIONS THEREOF
JP2007117022A (ja) リステリア・モノサイトゲネス検出のためのプライマーセットおよび方法
EP2678445B1 (fr) Procédé de quantification d'adn humain
KR20120035101A (ko) 리스테리아 종을 검출하기 위한 올리고뉴클레오티드들 및 그의 용도
US9845510B2 (en) Compositions and methods for rapid detection of Salmonella
US20160348189A1 (en) Molecular detection of rna
JP4212648B2 (ja) 遺伝標識および大腸菌血清型―０１５７：ｈ７の検出方法
Prasad et al. DNA based methods used for characterization and detection of food borne bacterial pathogens with special consideration to recent rapid methods
Hassan et al. Loop-mediated isothermal amplification (LAMP): Comparative advances over conventional PCR and other molecular techniques
US20220315991A1 (en) Detecting Salmonella from an Environmental Sample
EP3438280B1 (fr) Procédé de détection d'hémoplasme
WO2022211796A1 (fr) Détection de salmonella à partir d'un échantillon environnemental
Lübeck et al. PCR technology and applications to zoonotic food-borne bacterial pathogens
US20240117449A1 (en) Detecting Listeria Monocytogenes with Helicase-Dependent Amplification Assay
WO2004102149A2 (fr) Methodes et compositions permettant de detecter des especes bacteriennes
US20240117448A1 (en) Detecting cronobacter with helicase-dependent amplification assay
JP2007189980A (ja) 黄色ブドウ球菌検出のためのプライマーおよびそれを用いた検出法
KR101336948B1 (ko) 쉬겔라 소네이 검출방법
JP2008005779A (ja) ラクトバチルス・ブレビス検出のためのプライマーおよびそれを用いた検出法
JP6834164B2 (ja) Ｐｃｒ反応溶液の検出感度を維持する方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21935382

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21935382

Country of ref document: EP

Kind code of ref document: A1